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Centrioles are small microtubule-based cellular structures that form the centrosome, the cell’s 
major microtubule-organizing center responsible for forming the bipolar spindle in mitosis. Each 
centriole duplicates exactly once per cell cycle at the onset of S phase by forming one new 
centriole on the wall of each of the two pre-existing parental centrioles.  Polo-like kinase 4 
(PLK4) has emerged as an upstream master regulator of centriole biogenesis, but how PLK4’s 
activity is regulated to control centriole duplication specifically at the G1/S phase transition 
remains unclear. Here, we used CRISPR genome engineering to create a chemical genetic 
system in which endogenous PLK4 can be specifically inhibited using a cell-permeable ATP 
analog. Using this system, we demonstrate that the centriolar localization of the core centriole 
component STIL requires continued PLK4 activity. Most importantly, we show that direct 
binding of STIL to PLK4 activates PLK4 by promoting self-phosphorylation of the kinase’s 
activation loop. PLK4 subsequently phosphorylates STIL at two distant sites to promote 
centriole assembly.  One site allows STIL to bind to and recruit SAS6, the major component of 
the centriolar cartwheel, the inner framework of the centriole governing its architecture.  The 
other site allows STIL to increase its binding to and promote the stable integration of CPAP, the 
centriole protein that links the cartwheel to the centriole’s outer microtubule walls.  Thus, our 
findings describe the first key steps in the initiation of centriole assembly through activation of 
PLK4 and identify STIL as the first in vivo substrate of PLK4.  
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Centrioles are among the most distinctive structures in the animal cell and are characterized by 
an evolutionarily conserved nine-fold rotational symmetry (Gönczy 2012). In cycling cells, a pair 
of centrioles forms the core of the centrosome, the cell’s major microtubule-organizing center. 
This centriole pair duplicates once in each cell cycle by forming one new centriole on the wall of 
each of the two pre-existing parental centrioles (Nigg and Raff 2009; Tsou and Stearns 2006). 
This tightly coordinated process ensures that the single interphase centrosome reproduces exactly 
once prior to mitosis. The two centrosomes then separate and instruct the formation of the 
bipolar spindle apparatus upon which chromosomes are segregated. Abnormalities in centriole 
duplication can result in the production of extra copies of centrosomes, a feature commonly 
observed in human cancers and widely implicated in contributing to the pathogenesis of the 
disease (Basto et al. 2008; Castellanos, Dominguez, and Gonzalez 2008; Chan 2011; Ganem, 
Godinho, and Pellman 2009; Godinho et al. 2014; Silkworth et al. 2009).  
 
Pioneering work in C.elegans has led to the identification of a conserved set of five core proteins 
required for centriole assembly: ZYG-1/PLK4, SPD2/CEP192, SAS6, SAS5/STIL/Ana2, and 
SAS4/CPAP (Dammermann et al. 2004; Delattre et al. 2004; Kemp et al. 2004; Kirkham et al. 
2003; Leidel et al. 2005; Leidel and Gönczy 2003; O’Connell et al. 2001). Of these components, 
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ZYG-1/PLK4 has emerged as a central, upstream regulator of centriole biogenesis. The 
abundance of PLK4 must be carefully controlled: reducing PLK4 levels leads to a failure of 
centriole duplication, while PLK4 overexpression drives the formation of multiple centrioles in a 
single cycle (Bettencourt-Dias et al. 2005; Habedanck et al. 2005; Kleylein-Sohn et al. 2007; 
O’Connell et al. 2001; Peel et al. 2012). PLK4 levels are self-regulated by a negative feedback 
loop in which the kinase phosphorylates itself to trigger capture by an E3 ubiquitin ligase, 
leading to ubiquitylation and destruction of the active kinase (Cunha-Ferreira et al. 2013, 2009; 
Guderian et al. 2010; Holland et al. 2012; Klebba et al. 2013; Rogers et al. 2009). 
 
In early G1 phase, PLK4 is localized around the entire wall of the parental centriole and 
transitions at the beginning of S phase to an asymmetric spot on the parental centriole that marks 
the site of cartwheel assembly (T.-S. Kim et al. 2013; Ohta et al. 2014; K. F. Sonnen et al. 2013). 
The cartwheel appears at the beginning of procentriole assembly and is formed by the 
oligomerization of the centriole protein SAS6 (Daiju Kitagawa et al. 2011; Van Breugel et al. 
2011; van Breugel et al. 2014). In C.elegans and Drosophila, SAS6 interacts directly with 
another cartwheel protein SAS5/Ana2(Leidel et al. 2005; Stevens, Roque, and Raff 2010). While 
initial studies failed to detect a direct interaction between STIL (the human counterpart of 
SAS5/Ana2) and SAS6 (C. Arquint et al. 2012; Tang et al. 2011), it was recently reported that 
phosphorylation of the conserved STAN domain of STIL/Ana2 creates a binding site for SAS6 
that is required for SAS6 recruitment to the site of procentriole assembly (Dzhindzhev et al. 
2014; Ohta et al. 2014). PLK4 was also shown to phosphorylate STIL in vitro and when 
overexpressed in cells (Dzhindzhev et al. 2014; Kratz et al. 2015; Ohta et al. 2014). 
Nevertheless, PLK4 is a low-abundance enzyme and it remains unclear if endogenous PLK4 
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phosphorylates the STIL STAN domain in vivo. Furthermore, PLK4 localizes to the centriole 
throughout the cell cycle in human cells (C. Arquint et al. 2012), but how its activity is regulated 
to trigger procentriole formation remains unknown. A major limitation in addressing these 
questions is the lack of tools to rapidly and specifically control PLK4 kinase activity in vivo. 
 
A recent study reported the development of CFI-400945, a potent small-molecule ATP-
competitive inhibitor of PLK4 kinase activity (Laufer et al. 2013). However, along with 
inhibiting PLK4, CFI-400945 also strongly inhibited Aurora B kinase both in vitro and in vivo, 
complicating the use of this inhibitor for studying PLK4 targets in cells (Holland and Cleveland 
2014). We previously showed that the mutation of a single amino acid in the ATP-binding 
pocket of PLK4 creates an analog-sensitive (AS) kinase that can be inhibited in a highly specific 
manner with cell-permeable, non-hydrolyzable, bulky ATP analogs (Holland et al. 2010). In this 
chapter, we knock-in the AS mutation into both endogenous PLK4 alleles in a human cell line. 
Upon inhibition of PLK4 we find that STIL is acutely displaced from the centriole.  We further 
characterize the relationship between STIL and PLK4 and find that PLK4 binds to a conserved 
coiled-coil domain within STIL (Ohta et al. 2014).  Most importantly, we show that STIL 
binding activates PLK4 kinase activity.  Given that STIL is degraded after mitosis and 
accumulates at the beginning of S phase, our data offer a molecular basis for controlling the 
timing of PLK4 activation and centriole assembly.   
 
1.2 A chemical genetics system for controlling PLK4 activity in cells 
 
To study the function of PLK4 kinase activity in cells, we used CRISPR/Cas9 genome 
engineering to knock-in the PLK4 AS mutation (L89G) into both endogenous PLK4 alleles in 
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the DLD-1 colon cancer cell line (Figure 1A). Two homozygous PLK4
AS/AS
 clones were 
identified that behaved similarly in all assays and are hereafter presented together. Importantly, 
PLK4
AS/AS
 cells underwent normal centriole duplication demonstrating the functionality of the 
PLK4
AS
 allele in vivo (Figure 1B,C).  
 
Inhibition of PLK4 kinase activity leads to an increase in the level of the kinase (Holland et al. 
2010).  We therefore used the abundance of PLK4 at the centrosome as a readout of kinase 
inhibition. Treatment of PLK4
WT/WT
 cells with 10 µM of the bulky purine analog 3MB-PP1 did 
not affect centriole number or PLK4 levels (Figure 1B,D). By contrast, treatment of PLK4
AS/AS
 
cells with increasing concentrations of 3MB-PP1 led to a dose-dependent increase in PLK4 
levels at the centrosome. Maximal PLK4 stabilization was achieved at 0.2 µM 3MB-PP1 
indicating complete inhibition of PLK4 activity at this dose (Figure 1D). Consistently, 
PLK4
AS/AS
 cells treated with 0.2 µM 3MB-PP1 for one cell cycle failed centriole duplication (> 
70% cells contained 0-2 centrioles in mitosis) (Figure 1B,C). Treatment of PLK4
AS/AS
 cells with 
lower doses of 3MB-PP1 partially increased PLK4 abundance and gave rise to modest centriole 
amplification in mitotic cells (> 20% of cells treated with between 0.025 - 0.1 µM of 3MB-PP1 
contained > 4 centrioles in mitosis) (Figure 1B-D). This effect may be due to the formation of 
heterodimers between kinase inactive and catalytically-active PLK4 that leads to an increase in 
the abundance of the wild type (WT) kinase (Guderian et al. 2010; Laufer et al. 2013). 
 
1.3 Human DLD-1 cells continue to proliferate in the absence of centrioles 
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Recent work has shown that loss of the p53 tumor suppressor is necessary for the proliferation of 
cells lacking centrioles (Bazzi and Anderson 2014; Izquierdo et al. 2014). DLD-1 cell lines 
express a mutant form of p53 with compromised function (Sur et al. 2009). Consequently, 
chronic treatment of DLD-1 PLK4
AS/AS
 cells with 3MB-PP1 resulted in the step-wise reduction 
in centriole number as cells failed centriole duplication but continued to divide (Figure 2A-B). 
The cell cycle profile of PLK4
AS
 cells was unaltered at day 5 after 3MB-PP1 addition, by which 
point > 90 % of cells lacked centrioles (Figure 2A-C). DLD-1 PLK4
AS/AS
 cells lacking centrioles 
exhibited a significant increase in the level of aneuploidy and a modestly reduced proliferation 
rate (Figure 1E and 2D) but had no reduction in long-term clonogenic survival capability 
(Figure 2E-F). These data are consistent with the view that centrosomes are not essential for cell 
growth, but increase the fidelity of chromosome segregation (Debec, Sullivan, and Bettencourt-
Dias 2010; Khodjakov and Rieder 2001; Sir et al. 2013). Strikingly, washout of 3MB-PP1 in 
acentriolar DLD-1 cells led to the reactivation of PLK4 and the formation of de novo centrioles 
(Figure 2G). PLK4 activity is therefore dose-limiting for canonical and de novo centriole 
biogenesis. 
 
1.4 The centriole localization of STIL requires PLK4 kinase activity 
 
To determine which proteins require PLK4 kinase activity for centriole recruitment, we inhibited 
PLK4 for one hour and measured the abundance of 12 proteins at the centrosome of S/G2 cells 
(Figure 1F). As expected, one hour after inhibiting PLK4, the abundance of the kinase at the 
centriole increased. RNAi depletion of STIL has been reported to dramatically decrease the 
centriole-localized pool of SAS6 (C. Arquint et al. 2012; Tang et al. 2011; Vulprecht et al. 
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2012). Surprisingly, while the abundance of STIL at the centriole declined to 26% of control 
levels one hour after inhibition of PLK4, the abundance of SAS6 declined to only 72% in the 
same time period (Figure 1F). Prolonged treatment with 3MB-PP1 led to a progressive decline 
in the level of SAS6 at the centriole, reaching 31% of control levels by 2 days after 3MB-PP1 
addition (Figure 2H). Importantly, STIL and SAS6 cellular protein levels were not altered after 
chronic PLK4 inhibition (Figure 1G). We conclude that unlike SAS6, STIL dissociates from the 
centriole with extremely rapid kinetics following PLK4 inhibition. 
 
1.5 PLK4 directly binds and facilitates the recruitment of STIL to the 
centriole 
 
Since PLK4 kinase activity is required for the recruitment of STIL to the centriole, we 
investigated whether STIL and PLK4 form a complex in cells. Cells were transfected with full-
length Myc-GFP-STIL and either kinase active (PLK4
WT
) or kinase dead (PLK4
KD
) PLK4-
mCherry. Both active and inactive PLK4-mCherry co-purified with Myc-GFP-STIL (Figure 
3A). PLK4 is a suicide kinase that promotes its own destruction through self-phosphorylation of 
a 24 a.a. multi-phosphodegron (MPD) (Holland et al. 2010). As expected, deletion of the MPD 
(a.a. S282-S305) specifically stabilized kinase active PLK4 (PLK4
Δ24,WT
) and increased the 
amount of active PLK4
 
that co-immunoprecipitated with Myc-GFP-STIL (Figure 3A). To 
examine whether PLK4 directly associates with STIL we performed GST-pull down assays in 
the absence of ATP using purified recombinant STIL and GST-PLK4. GST-PLK4 could 
specifically pull-down STIL demonstrating a direct, kinase-independent association (Figure 3B). 
Together these data show that PLK4 and STIL form a complex independent of PLK4 kinase 
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activity. This contrasts with a recent study that proposed PLK4 interacted with STIL in a kinase-
activity-dependent manner (Ohta et al. 2014). 
 
To map the domain of STIL that interacts with PLK4, cells were transfected with a series of 
Myc-GFP-STIL truncation constructs and the interaction with PLK4
KD
-mCherry examined. 
Using this approach we mapped amino acids 715-850 as a region of STIL sufficient for binding 
to PLK4 (Figure 3C,D). This region contains a highly conserved sequence (a.a. 721-746) that 
forms a predicted coiled-coil (Figure 4A). Deletion of a.a. 721-746 (ΔCC) from full-length Myc-
GFP-STIL decreased binding to both kinase active and inactive PLK4
Δ24
-mCherry (Figure 
4B,C). We next analyzed whether PLK4 binding was required for the localization of STIL to the 
centriole. Myc-GFP-STIL WT and ΔCC were expressed in cells depleted of endogenous STIL 
by siRNA. Deletion of the predicted coiled-coil domain reduced the abundance of STIL at the 
centriole to 6% of that observed in control cells and failed to rescue centrosome duplication in 
cells depleted of endogenous STIL (Figure 4D,E). We conclude that binding to PLK4 is 
necessary for the centriole targeting and function of STIL. 
 
1.6 STIL binding to PLK4 promotes kinase activity 
 
Co-transfection of Myc-GFP-STIL reduced the abundance of PLK4
WT
 by 50%, but had little 
effect on the level of PLK4
KD
 (Figure 5A,B). Since PLK4 promotes its own destruction, we 
hypothesized that STIL expression stimulated PLK4 kinase activity and thus destruction. To test 
this hypothesis, we first examined the abundance of stably overexpressed PLK4-EYFP in the 
presence and absence of STIL. The total cellular pool, and levels of centrosome-localized PLK4-
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EYFP increased dramatically following STIL siRNA (Figure 5C). To test whether STIL 
regulates the abundance of endogenous PLK4, Myc-GFP-STIL WT and ΔCC were expressed in 
cells depleted of STIL. STIL knockdown increased the level of endogenous PLK4 at the 
centrosome (Figure 5D), while overexpression of Myc-GFP-STIL WT decreased the abundance 
of centrosomal PLK4. This decrease required STIL binding to PLK4 as overexpression of Myc-
GFP-STIL
ΔCC
 had little effect on PLK4 levels (Figure 5D). 
 
To test if STIL was capable of promoting PLK4 self-phosphorylation, we stabilized kinase active 
PLK4 by deletion of the PLK4 MPD (PLK4
Δ24,WT
). Strikingly, expression of Myc-GFP-STIL 
dramatically reduced the mobility of kinase active PLK4
Δ24
-mCherry in a SDS-PAGE gel, but 
had no effect on the mobility of kinase dead PLK4
Δ24
-mCherry (Figure 5E). Treatment with λ-
phosphatase abolished the electrophoretic mobility shift, demonstrating that the slower migration 
of PLK4
Δ24
-mCherry was a result of increased kinase self-phosphorylation. To establish whether 
STIL binding stimulates PLK4 activity, we co-expressed PLK4
Δ24,WT
-mCherry with Myc-GFP-





 mutant that was defective in PLK4 binding did not 
(Figure 5F). Importantly, a fragment of Myc-GFP-STIL (a.a. 715-988) that contains the coiled-
coil domain and interacts with PLK4 was unable to activate the kinase, suggesting that binding to 
the STIL coiled-coil is not, in itself, sufficient to activate PLK4 (Figure 5F). We conclude that 
STIL binding to PLK4 stimulates kinase activity and subsequent destruction of the kinase. 
 
PLK4 kinase activity requires phosphorylation of threonine 170 in the activation loop (T-loop) of 
the kinase domain (Nakamura, Saito, and Takekawa 2013; Swallow et al. 2005). We therefore 
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tested whether STIL binding promotes PLK4 T170 phosphorylation. PLK4
Δ24
-mCherry was co-
transfected with or without Myc-GFP-STIL and immunoprecipitated PLK4 was probed with an 
antibody that recognizes phosphorylated T170 (pT170) (Nakamura, Saito, and Takekawa 2013). 
Importantly, expression of Myc-GFP-STIL WT dramatically increased phosphorylation of T170 
on kinase active, but not inactive PLK4
Δ24 
(Figure 5G). By contrast, expression of the Myc-
GFP-STIL
ΔCC
 mutant that was defective in PLK4 binding was unable to promote PLK4-
mediated T170 phosphorylation. These data suggest that STIL binding stimulates PLK4 T170 
self-phosphorylation leading to increased PLK4 activity.  
 
Human PLK4 is targeted to the centriole through a direct interaction with the acidic N-terminal 
region of CEP152 and CEP192 (Cizmecioglu et al. 2010; Dzhindzhev et al. 2010; Hatch et al. 
2010; T.-S. Kim et al. 2013; K. F. Sonnen et al. 2013). However, while Myc-GFP-STIL, Myc-
GFP-CEP152 and Myc-GFP-CEP192 all formed a complex with PLK4
Δ24,KD
-mCherry in cells, 
STIL was the only PLK4 binding partner that significantly stimulated self-phosphorylation of 
PLK4
Δ24




STIL is an in vivo regulator of PLK4 kinase activity 
An important unanswered question is how PLK4 kinase activity is temporally controlled to 
promote centriole assembly. Our findings reveal that direct binding of PLK4 to STIL stimulates 
PLK4 kinase activity by promoting self-phosphorylation of the activation loop of the PLK4 
kinase domain (Figure 5E and G). In cycling cells, STIL accumulates in late G1/early S phase 
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and is then degraded after anaphase onset (Arquint and Nigg 2014; C. Arquint et al. 2012; Tang 
et al. 2011). We therefore speculate that the cell cycle-regulated accumulation of STIL could 
provide the trigger for activation of PLK4 at the G1/S boundary. How STIL binding promotes 
PLK4 activation remains unclear. One possibility is that the binding of STIL triggers a 
conformational change in PLK4 that positions the PLK4 activation loop for optimal self-
phosphorylation. Alternatively, STIL may promote the recruitment of an additional factor that 
serves to activate PLK4. 
 
At the G1/S border, centriolar PLK4 transitions from a ring-like arrangement to a single focus on 
the wall of the parental centriole (T.-S. Kim et al. 2013; Ohta et al. 2014; K. F. Sonnen et al. 
2013). Understanding how this transition is controlled is central to understanding how a single 
new centriole is created on each parental centriole. Since STIL binding stimulates PLK4 kinase 
and subsequent destruction (Figure 5A), STIL recruitment may lead to the activation and 
destruction of PLK4 that is localized around the wall of the parental centriole. Consistently, it 
was recently shown that depletion of STIL prevented the formation of a single focus of PLK4 
(Ohta et al. 2014). How a single focus of PLK4 is protected from auto-destruction remains an 
important question for future studies. 
 
PLK4 kinase activity is not required for continued growth of DLD-1 colon cancer cells 
While the abundance of PLK4 is normally carefully controlled, alterations in PLK4 expression 
has been reported in several tumor types, prompting proposals that PLK4 inhibition may be an 
effective anticancer therapy. Surprisingly, we now show that specific inhibition of PLK4 kinase 
activity in a human cancer cell line with compromised p53 function results in a complete loss of 
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centrioles and centrosomes, but only modestly reduced cell growth (Figure 1B and E). This 
demonstrates that PLK4 and centrioles are not essential for cell cycle progression, at least in 
transformed cells. It therefore remains to be determined whether PLK4 inhibition will be a useful 




1.8 Figures and Legends 
 
 
Figure 1. PLK4 kinase activity is required to maintain STIL at the centriole. 
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(A) Schematic of the strategy used to knock-in the analog-sensitive (AS) mutation into both 
alleles of PLK4 in human DLD-1 cells. The repair oligonucleotide introduced the AS mutation 
(L89G), a silent AflIII restriction site and a mutation in the protospacer adjacent motif (PAM) to 





 cells were treated with 3MB-PP1 for 20 hours and nocodazole 
added for the final 4 hours of the treatment. Graph shows the fraction of mitotic cells with the 
indicated number of centrioles. Bars represent the mean of three independent experiments with > 
20 cells counted per experiment.  
(C) Selected images of mitotic PLK4
AS/AS
 cells from (B) stained with Centrin and CEP192.  
Scale bar for large images, 5 μm.  Scale bar for small images, 0.5 µm. 
(D) Quantification of the relative levels of PLK4 at the centrosome of interphase cells 20 hours 
after addition of 3MB-PP1. Bars represent the mean of at least three independent experiments 
with > 40 cells counted per experiment.  
(E) Graph showing the increase in cell number at various times after addition of 3MB-PP1. 
Points show the mean of at least three independent experiments.  
(F) Quantification of relative protein abundance at the centrosome of S/G2 phase cells 1 hour 
after addition of 3MB-PP1. Bars represent the mean of three independent experiments with > 40 
cells counted per experiment. 
(G) Immunoblot showing no change in the level of endogenous STIL and SAS6 at 1 or 2 days 





Figure 2. Continued growth of DLD-1 cells in the absence of PLK4 kinase activity.  
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(A-B) Quantification of the fraction of interphase cells that lack Centrin and CEP192 foci 
(Acentriolar) at various times after 3MB-PP1 addition. Bars represent the mean of three 
independent experiments with > 50 cells counted per experiment 




 cells after 5 days of 3MB-PP1 
treatment. Profiles shown are taken from a single representative experiment that was repeated 
three times. 
(D) Chromosome counts of PLK4
AS/AS
 cells.  This experiment was completed once with at least 
n=60 cells per condition. 
(E) Images of crystal violet-stained colonies formed two weeks after addition of 3MB-PP1. Scale 
bar, 2 cm. 
(F) Quantification of the percent clonogenic survival of the indicated cell lines. Bars represent 
the mean of at least two independent experiments carried out in triplicate. 
(G) Quantification of the number of Centrin foci per cell at various times after 3MB-PP1 
washout. Bars represent the mean of two independent experiments with > 50 cells counted per 
experiment. 
(H) Quantification of the relative levels of STIL and SAS6 at the centrosome of S/G2 phase cells 
at various times after addition of 3MB-PP1. Bars represent the mean of two independent 






Figure 3. PLK4 directly binds to STIL in vitro and in vivo. 
(A) Cells were co-transfected with the indicated constructs and subject to co-
immunoprecipitation analysis with the indicated antibodies.   
(B) GST-PLK4 was incubated with STIL in vitro and GST pull-downs analyzed by Coomassie 
staining.  
(C-D) Cells were co-transfected with the indicated constructs and subject to co-






Figure 4. The coiled-coil domain of STIL is required for binding to PLK4. 
(A) Schematic of STIL showing an alignment of the conserved STIL coiled-coil domain. 
(B-C) Cells were co-transfected with the indicated constructs and subject to co-
immunoprecipitation analysis with the indicated antibodies. 
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(D) Endogenous STIL was depleted by siRNA and replaced with either Myc-GFP-STIL WT or 
ΔCC. Graph shows quantification of the relative levels of Myc-GFP-STIL at the centrosome of 
S/G2 phase cells. Bars represent the mean of at least three independent experiments with > 40 
cells counted per experiment.  
(E) Quantification showing the number of CEP192 foci in cells in which endogenous STIL had 
been depleted and replaced with the indicated Myc-GFP-STIL transgene. Bars represent the 
mean of three independent experiments with > 100 cells counted per experiment. 
(F) Cells were co-transfected with the indicated constructs and subject to co-






Figure 5. STIL binding stimulates PLK4 activity. 
(A) Cells were co-transfected with the indicated constructs and protein levels analyzed by 
immunoblot. mCherry-Mad2 serves as a transfection control.  
(B) Quantification of protein levels shown in (A). Bars represent the mean of three independent 
experiments. 
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(C) STIL was depleted by siRNA and 24 hours later doxycycline added to induce expression of 
PLK4-EYFP. Immunoblot shows the relative levels of STIL and PLK4-EYFP in control or STIL 
siRNA depleted cells. Graph shows quantification of the relative level of PLK4-EYFP at the 
centrosome of S/G2 phase cells. Bars represent the mean of at least three independent 
experiments with > 40 cells counted per experiment. 
(D) Endogenous STIL was depleted by siRNA and replaced with either Myc-GFP-STIL WT or 
ΔCC using the scheme outlined in Figure 8A. Graph shows quantification of the relative levels 
of PLK4 at the centrosome of S/G2 phase cells. Bars represent the mean of at least three 
independent experiments with > 40 cells counted per experiment. 
(E-F) Cells were co-transfected with the indicated constructs and protein levels analyzed by 
immunoblot. Where indicated, lambda protein phosphatase (λ PP) was incubated with the cell 
lysate for 60 minutes prior to immunoblotting. 
(G-H) Cells were co-transfected with the indicated constructs and subjected to co-
immunoprecipitation analysis with the indicated antibodies. 
(I) Cells were co-transfected with the indicated constructs and protein levels analyzed by 




Chapter 2. PLK4 Phosphorylates STIL to 





In the previous chapter, we found that STIL is an in vivo activator of PLK4 kinase activity and 
we propose a model by which accumulating levels of STIL in the cytoplasm in G1 phase could 
peak at the onset of S phase and trigger PLK4 activity to initiate centriole assembly at the correct 
time in the cell cycle (Figure 10C) (Tang et al. 2011; C. Arquint et al. 2012).  While further 
experimentation is required to rigorously examine this hypothesis, the question remains as to 
how PLK4 activity promotes centriole duplication.  Substrates have been proposed for PLK4 
(Bahtz et al. 2012; Cizmecioglu et al. 2010; Hudson et al. 2001; Puklowski et al. 2011), but what 
specific sites PLK4 phosphorylates in vivo and how these phosphorylation events lead to 
cartwheel assembly has not been shown.   
 
An obvious candidate substrate of PLK4 is SAS6, the major structural component of the 
cartwheel (Daiju Kitagawa et al. 2011; Van Breugel et al. 2011; van Breugel et al. 2014).  One 
could imagine that PLK4 could phosphorylate SAS6 to promote its homo-oligomerization. 
However, crystal structures of the oligomeric interface of SAS6 have few accessible serines or 
threonines (Van Breugel et al. 2011; van Breugel et al. 2014; Daiju Kitagawa et al. 2011), and it 
is not clear how phosphorylation would support this interaction. 
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In this chapter, we find that PLK4 phosphorylates STIL, but not SAS6, in vitro.  Using phospho-
specific antibodies, we demonstrate that the highly conserved STIL STAN domain is a target of 
endogenous PLK4 in vivo. Importantly, we demonstrate that PLK4-mediated phosphorylation of 
the STIL STAN domain promotes direct binding of STIL to SAS6 and leads to SAS6 
recruitment to the site of cartwheel assembly.  Thus, STIL is both and activator and a substrate of 
PLK4.  
 
2.2 PLK4 phosphorylates the STIL STAN domain in vivo 
 
Given that STIL directly binds and stimulates PLK4 activity, we investigated whether PLK4 
phosphorylates STIL to control centriole assembly. We mapped in vitro PLK4 phosphorylation 
sites on STIL using mass spectrometry (Figure 6A). STIL-related proteins show high sequence 
homology in a short ~90 a.a. region known as the STAN (STIL/Ana2) motif (Stevens et al. 
2010). This region contains five conserved residues that are phosphorylated in cells: S1103, 
S1108, S1111, S1116 and T1119 (Hoffert et al. 2006; Huttlin et al. 2010) (Figure 7A). Of these 
five sites, S1108 and S1116 were phosphorylated by PLK4 in vitro and closely matched the 
PLK4 consensus phosphorylation sequence (Johnson et al. 2007; Kettenbach et al. 2012). To 
facilitate analysis of these phosphorylation sites we generated phospho-specific antibodies. The 
affinity purified pS1108 and pS1116 antibodies recognized recombinant GST-STIL and GST-
STIL C-term only in the presence of kinase active PLK4 (Figure 7B and 6B). Moreover, 
recognition of phosphorylated GST-STIL C-term by the pS1108 and pS1116 antibody was 
abolished by mutation of S1108A and S1116A, respectively (Figure 7B). These observations 
confirm that PLK4 phosphorylates STIL at S1108 and S1116 in vitro, and demonstrate the 
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specificity of the pS1108 and pS1116 antibodies for revealing the phosphorylation status of 
STIL. 
 
The pS1116 antibody recognized Myc-GFP-STIL WT immunoprecipitated from cells, but not 
Myc-GFP-STIL containing a S1116A mutation (Figure 7D). To establish whether PLK4 was 





with 3MB-PP1 and examined phosphorylation of STIL S1116. Treatment with 3MB-PP1 
abolished phosphorylation of Myc-GFP-STIL S1116 in PLK4
AS/AS
 cells, but did not affect 
phosphorylation of this site in PLK4
WT/WT
 cells, demonstrating that PLK4 phosphorylates STIL 
S1116 in cells (Figure 7D). Deletion of the coiled-coil region of STIL abolished phosphorylation 
of STIL S1116, suggesting that phosphorylation of this site requires PLK4 binding to STIL 
and/or the recruitment of STIL to the centriole (Figure 7E). 
 
While the pS1116 antibody detected phosphorylated STIL by immunoblot, it cross-reacted with 
an additional phosphorylated centriole protein and consequently was not useful for 
immunofluorescence analysis. We therefore tested whether the pS1108 antibody could detect 
phosphorylation of STIL S1108 by immunofluorescence staining. The pS1108 antibody stained a 
centriole-localized signal that co-localized with Myc-GFP-STIL (Figure 7F). To determine the 
specificity this staining, we replaced endogenous STIL with a WT or S1108A Myc-GFP-STIL 
transgene. When normalized to the total level of STIL at the centriole, the centriole-localized 
pS1108 signal was reduced by > 90% in cells expressing the S1108A mutant of Myc-GFP-STIL 
(Figure 7F). Moreover, treatment of PLK4
AS/AS
 cells with 3MB-PP1 for one hour resulted in a > 
90% reduction in STIL S1108 phosphorylation, demonstrating that STIL S1108 is a substrate for 
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PLK4 in vivo (Figure 7G). To investigate the cell-cycle dependent phosphorylation of STIL 
S1108 we carried out fluorescence intensity measurements to determine the level of Myc-GFP-
STIL and pS1108 at the centriole in late G1 (CENP-F negative) and S/G2 (CENP-F positive) 
cells (Hussein and Taylor 2002). While levels of Myc-GFP-STIL were higher in S/G2 compared 
with G1 cells, the level of pS1108 staining remained largely unchanged (Figure 7H,I). 
Importantly, we never observed centriole-localized Myc-GFP-STIL in the absence of pS1108 
staining. These data suggest PLK4 is active from late G1 through G2 phase. 
 
2.3 PLK4 phosphorylates the STIL STAN domain to promote centriole 
duplication 
 
We investigated how PLK4-mediated STIL phosphorylation affects centriole biogenesis. WT or 
phosphorylation defective Myc-GFP-STIL transgenes were integrated at a pre-defined genomic 
locus in a DLD-1 host cell line and expression induced by addition of doxycycline. All of the 
Myc-GFP-STIL transgenes were expressed at identical, near-endogenous levels (Figure 6C). 
Expression of Myc-GFP-STIL WT in the presence of endogenous STIL drove excessive 
centrosome formation in 45% of cells (Figure 6D). By contrast, expression of a Myc-GFP-STIL 
variant (5A) with all 5 phosphorylation sites in the STAN domain substituted to alanine had no 
effect on centrosome number (Figure 6D). Alanine substitutions at the S1108 or S1116 PLK4 
phosphorylation sites substantially reduced the ability of overexpressed Myc-GFP-STIL to 
promote centrosome amplification (reduced to 19% and 15%, respectively), indicating that 
phosphorylation of these sites is important for the function of STIL in centriole biogenesis. To 
further characterize STIL S1108 and S1116 phosphorylation sites, we introduced phospho-
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mimicking mutations at these positions and assayed the ability of the Myc-GFP-STIL constructs 
to promote centrosome overduplication. The S1108D mutation promoted centrosome 
amplification as efficiently as Myc-GFP-STIL WT (Figure 6D). On the other hand, the S1116D 
mutation was indistinguishable from an alanine substitution at this site, suggesting that either the 
S1116D substitution failed to mimic the phosphorylated state, or that centriole biogenesis 
requires dynamic regulation of S1116 phosphorylation. 
 
To address the role of PLK4-mediated STIL STAN domain phosphorylation in canonical 
centriole duplication, we replaced endogenous STIL with physiological levels of Myc-GFP-STIL 
transgenes (Figure 8A,B). Depletion of STIL led to a 47% increase in the number of cells with ≤ 
1 centrosome and this effect was completely rescued by expression of an RNAi-resistant Myc-
GFP-STIL WT transgene (Figure 8C). By contrast, expression of either Myc-GFP-STIL lacking 
the STAN domain (ΔSTAN, deletion of a.a. 1061-1147), or the Myc-GFP-STIL 5A mutant 
lacking 5 phosphorylation sites in this region, failed to rescue centriole duplication (Figure 8C). 
Single alanine substitutions at each of the five-phosphorylation sites in the STIL STAN domain 
revealed that S1116 was the most important phosphorylation site for controlling centriole 
duplication (53% of S1116A cells contain ≤ 1 centrosome) (Figure 8F). The Myc-GFP-STIL 
S1108A mutant was also partially defective in centriole duplication (32% S1108A cells contain 
≤ 1 centrosome) and this defect was further exacerbated when combined with the S1116A 
mutation (61% of S1108A/S1116A cells contain ≤ 1 centrosome) (Figure 8F). We conclude that 
PLK4-mediated phosphorylation of STIL S1116, and to a lesser extent STIL S1108, is required 
for centriole duplication.  
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2.4 PLK4 phosphorylation of the STIL STAN domain is required for centriole 
recruitment of STIL 
 
We next analyzed if STAN phosphorylation contributes to STIL centriole targeting. Since STIL 
is degraded after mitosis (Arquint and Nigg 2014; C. Arquint et al. 2012; Tang et al. 2011), we 
measured Myc-GFP-STIL levels in S/G2 cells marked by the presence of CENP-F (Hussein and 
Taylor 2002). While all WT and mutant Myc-GFP-STIL transgenes localized to the centriole in 
the absence of endogenous STIL, the relative abundance of each phosphorylation site mutant at 
the centriole varied considerably. Surprisingly, while deletion of the STAN domain did not alter 
the centriole abundance of STIL, mutation of 5 phosphorylation sites in this region reduced the 
abundance of centriole STIL to < 25% of that WT STIL (Figure 8D,E). The difference in 
centriole abundance of STIL 5A and STIL ∆STAN suggests that the STAN domain acts to 
inhibit STIL centriole localization and that phosphorylation of the STAN domain is able to 
overcome this inhibition to promote localization. Preventing phosphorylation of both the S1108 
and S1116 PLK4 phosphorylation sites reduced the abundance of STIL at the centriole to 32% of 
control cells (Figure 8G,H). This suggests that phosphorylation by PLK4 of S1108 and S1116 
overcomes the STAN domain mediated inhibition of STIL centriole localization. Taken together, 
these observations offer an explanation for why the centriole levels of STIL are reduced after 
PLK4 inhibition (Figure 1F).  
 
Mutating STIL S1108 to aspartic acid increased the centriolar abundance of Myc-GFP-STIL in 
excess of the WT protein (Figure 6E). Nevertheless, Myc-GFP-STIL S1108D was as defective 
in centriole duplication as the S1108A mutant protein, suggesting that STAN phosphorylation 
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performs functions in addition to centriole recruitment (Figure 6F). Since the Myc-GFP-STIL 
S1108D promoted centrosome amplification as effectively as Myc-GFP-STIL WT when 
overexpressed in the presence of endogenous STIL (Figure 6D), our data highlight differences in 
assays using STIL overexpression versus functional replacement. 
 
To examine how STAN domain phosphorylation affects the binding dynamics of centriolar 
STIL, we performed Fluorescence Recovery after Photobleaching in cells expressing Myc-GFP-
STIL transgenes. Myc-GFP-STIL WT and S1108A only partially recovered following bleaching, 
showing that STIL exists in both a mobile and immobile pool at the centriole (Figure 8I, Myc-
GFP-STIL WT R% = 48%, t1/2 = 127 s). Deletion of the STAN domain or mutation of the S1116 
phosphorylation site both increased the mobile fraction of centriolar STIL (Figure 8I, Myc-GFP-
STIL ΔSTAN R% = 93%, t1/2 = 110 s; Myc-GFP-STIL S1116A, R% = 69%, t1/2 = 80 s). 
Together, these data suggest that phosphorylation of the STAN domain is required for stable 
interaction of STIL with the centriole. The increased turnover of Myc-GFP-STIL ΔSTAN is 
likely to limit the centriolar accumulation of this mutant protein. This provides an explanation 
for why, despite loss of a domain that is inhibitory to centriole recruitment, Myc-GFP-STIL 
ΔSTAN localizes to the centriole to a similar level as Myc-GFP-STIL WT. 
 
2.5 Stable centriole recruitment of STIL requires direct binding of SAS6 
 
Recently, it was proposed that phosphorylation of the STIL/Ana2 STAN domain facilitates STIL 
binding to SAS6 (Dzhindzhev et al. 2014; Ohta et al. 2014). To test if phosphorylation of STIL 
S1108 and S1116 by PLK4 promotes the association of SAS6, we reconstituted SAS6 binding to 
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STIL in vitro. GST-STIL was incubated with kinase active or inactive PLK4 and then combined 
with SAS6. GST-STIL was then captured on beads and the association with SAS6 determined by 
immunoblotting. Incubation with kinase active but not kinase dead PLK4 promoted direct 
binding of SAS6 to GST-STIL (Figure 9A). To establish if SAS6 binding was dependent on 
phosphorylation of STIL S1108 or S1116, we tested the ability of SAS6 to bind in vitro to WT or 
phosphorylation site mutants of recombinant GST-STIL C-term (a.a. 898-1287). Phosphorylation 
of GST-STIL C-term by PLK4 increased the binding of SAS-6 by > 9-fold (Figure 9B). 
Importantly, mutation of STIL S1108A and S1116A reduced SAS6 binding to 37% and 22% of 
that observed with WT GST-STIL C-term (a.a. 898-1287). To map the domain of SAS6 that 
interacts with STIL, cells were transfected with a series of FLAG-SUMO-SAS6 truncation 
constructs and the interaction with Myc-GFP-STIL examined in the presence of PLK4
Δ24,WT
-
mCherry. Using this approach STIL binding was mapped to the C-terminal part of SAS6 protein 
(a.a. 316-657) (Figure 10A). We conclude that phosphorylation of the STIL STAN domain by 
PLK4 promotes direct binding of STIL to the C-terminal region of SAS6. 
 
We next analyzed the requirement of STIL phosphorylation for binding to SAS-6 in cells. 
Deletion of the STIL STAN domain or mutation of phosphorylation sites in this region did not 
affect STIL binding to PLK4, or activation of PLK4 kinase activity (Figure 9C). Expression of 
kinase active PLK4
Δ24
 promoted a ~2-fold increase in the binding of FLAG-SUMO-SAS6 to 
Myc-GFP-STIL (Figure 9C, lane 2 and 3). The Myc-GFP-STIL 5A mutant associated with 
SAS6 at only 23% of the level observed with Myc-GFP-STIL WT (Figure 9C, lane 2 and 7). 
Importantly, preventing phosphorylation of STIL S1116 alone also reduced SAS6 binding to a 
similar degree, while deletion of the STAN domain reduced SAS6 binding to 12% of that 
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observed with Myc-GFP-STIL WT (Figure 9C lane 2, 5 and 8). These data indicate that PLK4-
mediated phosphorylation of STIL S1116 plays a key role in promoting SAS6 binding to STIL. 
 
Finally, we investigated how PLK4-mediated phosphorylation of STIL contributes to SAS6 
recruitment to the centriole. We monitored the presence of PLK4 and SAS6 at the centriole of 
cells in which endogenous STIL had been functionally replaced with various Myc-GFP-STIL 
transgenes. Despite the fact that the centriolar abundance of the STIL transgenes varied 
dramatically (Figure 8G,H), cells contained near identical levels of endogenous centriolar PLK4 
(Figure 9D). Since binding to PLK4 is unaffected by STIL STAN domain phosphorylation 
(Figure 9C), our data suggest that abundance of centriolar PLK4 is mainly controlled through 
binding to STIL in the cytosol. In accord with previous reports, depletion of STIL dramatically 
reduced SAS6 recruitment to the centriole (an average of 13% SAS6 remaining) without altering 
SAS6 protein levels (Figure 9E and 10B). While expression of Myc-GFP-STIL WT rescued the 
centriole recruitment of SAS6 in cells depleted of endogenous STIL, the Myc-GFP-STIL 5A 
mutant failed to do so (19% centriolar SAS6 remaining) (Figure 9E,F). Preventing 
phosphorylation of STIL S1108 or S1116 also reduced SAS6 recruitment (64% and 36% of 
centriolar SAS6 remaining, respectively). This suggests that PLK4-mediated phosphorylation of 




Here, we have provided direct evidence to show that endogenous PLK4 directly phosphorylates 
STIL S1108 and S1116 in vivo and reveal two key roles for these phosphorylation events in 
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promoting centriole assembly (Figure 5G). First, phosphorylation of S1108 and S1116 increased 
the efficiency of STIL centriole targeting (Figure 4G,H). This explains why PLK4 kinase 
activity is required for the robust targeting of STIL to the centriole (Figure 1F). Second, and 
consistent with two recent reports (Dzhindzhev et al. 2014; Ohta et al. 2014), we show that 
phosphorylation of STIL S1108 and S1116 is required for subsequent binding of STIL to SAS6 
and for efficient recruitment of SAS6 to the centriole (Figure 5A,B). We speculate that STIL 
binding to SAS6 facilitates cartwheel assembly, leading to the stable incorporation of STIL into 
the centriole structure. 
 
In human cells, SAS6 is transiently recruited to the lumen of the mother centriole in early S 
phase, before repositioning to the outer wall of the mother centriole to initiate cartwheel 
formation and procentriole assembly (Fong et al. 2014). PLK4 and STIL are both required for 
the release of luminal SAS6. It is therefore tempting to speculate that STIL-mediated activation 
of PLK4 triggers the release of luminal SAS6 and subsequent capture by STIL at a site on the 
wall of the mother. Further studies will be required to test this idea.  
 
STIL localization to the centriole requires both PLK4 binding and STAN domain 
phosphorylation 
PLK4 has been shown to interact with a conserved coiled-coil domain in the central region of 
STIL (Kratz et al. 2015; Ohta et al. 2014). We demonstrate that PLK4 and STIL form a complex 
both in vitro and in vivo in the absence of PLK4 activity (Figure 3A,B). This contrasts with a 
previous study that indicated the binding of PLK4 to STIL required PLK4 kinase activity (Ohta 
et al. 2014). While the reason for this discrepancy remains unclear, we note that in C.elegans, 
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ZYG-1/PLK4 binds directly to the coiled-coil of SAS6 independent of kinase activity (Lettman 
et al. 2013). It is thus tempting to speculate that while the location of the ZYG-1/PLK4 binding 
site differs, a conserved role of the ZYG-1/PLK4-SAS5/STIL-SAS6 module is to position ZYG-
1/PLK4 for optimal phosphorylation of SAS5/STIL family proteins. 
 
A mutant form of STIL lacking the central coiled-coil had a dramatically reduced localization to 
the centriole, suggesting that PLK4 may act as a centriole receptor for STIL (Figure 4D). In 
flies, Ana2/STIL localizes to the centriole in the absence of phosphorylation by PLK4 
(Dzhindzhev et al. 2014). In addition, a study in human cells reported that phosphorylation of the 
STIL STAN domain was not required for centriole targeting of STIL. How, then, do we explain 
the observation that PLK4 activity is also required for the localization of STIL to the centriole 
(Figure 1F)? Our evidence shows that, although not essential for STIL centriole recruitment, 
phosphorylation of the STAN domain by PLK4 dramatically increased the efficiency of STIL 
centriole targeting (Figure 4G,H). Importantly, we show that PLK4 binding to STIL does not 
require STIL STAN domain phosphorylation (Figure 5C), demonstrating that centriole targeting 
of STIL requires both PLK4 binding and phosphorylation of its STAN domain by PLK4.  
 
How does phosphorylation of the STAN domain control the localization of STIL? We speculate 
that cytoplasmic STIL exists in an auto-inhibited conformation that prevents recruitment to the 
centriole (Figure 6). Deletion of the STIL STAN domain or phosphorylation of this region by 
PLK4 is proposed to release this auto-inhibition to allow efficient centriole targeting. 
Phosphorylation of the STIL STAN domain also triggers the binding of STIL to SAS6. This 
interaction could promote cartwheel assembly and lead to the stable incorporation of STIL in the 
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cartwheel structure (Figure 6). This explains why STIL mutants that are defective in STAN 
domain phosphorylation have a reduced pool of protein stably bound at the centriole (Figure 4I).  
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Figure 6. STIL phosphorylation is required for centriole duplication. 
(A) GST-SAS6, GST-STIL or GST-STIL C-term (a.a. 898-1287) was phosphorylated in vitro 
with kinase active or inactive His-PLK4. Coomassie (CBB) stained gel shows the purified 
protein and autoradiogram (
32
P) shows the incorporation of γ-
32
P-ATP. 
(B) GST-STIL was phosphorylated in vitro with kinase active or inactive His-PLK4 and 
analyzed by immunoblot with the indicated antibodies.  
(C) Expression of Myc-GFP-STIL was induced for 48 hours with doxycycline and protein levels 
analyzed by immunoblot. 
(D) Quantification of the fraction of cells with > 2 centrosomes 48 hours after induction of Myc-
GFP-STIL expression with doxycycline (Dox). Bars show the mean of three independent 
experiments with > 50 cells counted per experiment. 
(E) Quantification from (E) showing the relative level of Myc-GFP-STIL at the centrosome of 
S/G2 phase cells. Bars represent the mean of at least three independent experiments with > 40 
cells counted per experiment. The Myc-GFP-STIL S1108 and S1116 mutants from Figure 8H are 
shown alongside as a comparison. All error bars in the figure represent the S.E.M. 
(F) Quantification showing the number of CEP192 foci in cells in which endogenous STIL had 
been depleted and replaced with the indicated Myc-GFP-STIL transgene. Bars represent the 
mean of at least three independent experiments with > 100 cells counted per experiment. The 






Figure 7. PLK4 phosphorylates the STIL STAN domain in vivo. 
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(A) Schematic of STIL showing the CPAP binding domain, coiled-coil domain (CC) and the 
conserved STAN domain. Alignment shows the position of five amino acids in the STAN 
domain that are phosphorylated in vivo. 
(B) GST-STIL C-term (a.a. 898-1287) was phosphorylated in vitro with kinase active or inactive 
His-PLK4 and analyzed by immunoblot with the indicated antibodies. Coomassie (CBB) stained 
gel shows the purified protein. 
(C) Myc-GFP-STIL WT or S1116A was immunopurified from cells and analyzed by 





 cells were treated with 3MB-PP1 for 1 hour. Myc-GFP-STIL was 
then immunopurified from cells and analyzed by immunoblotting with the indicated antibodies. 
(E) Myc-GFP-STIL WT or ΔCC was immunopurified from cells and analyzed by 
immunobloting with the indicated antibodies.  
(F) (Left) Endogenous STIL was replaced with either Myc-GFP-STIL WT or S1108A. Graph 
shows quantification of the relative levels of pS1108/STIL at the centrosome of S/G2 phase 
cells. Bars represent the mean of at least three independent experiments with > 40 cells counted 
per experiment. (Right) Selected images of cells showing Myc-GFP-STIL and pS1108 staining. 
Left images, scale bar, 5 μm.  Right images, scale bar, 0.5 µm. 
(G) (Left) PLK4
AS/AS
 cells were treated with or without 3MB-PP1 for 1 hour. Graph shows 
quantification of the relative levels of pS1108/STIL at the centrosome of S/G2 phase cells. Bars 
represent the mean of at least three independent experiments with > 40 cells counted per 
experiment. (Right) Selected images of cells showing Myc-GFP-STIL and pS1108 staining. Left 
images, scale bar, 5 μm.  Right images, scale bar, 0.5 µm. 
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(H) (Left) Quantification showing the relative levels of Myc-GFP-STIL and pS1108 at the 
centrosome of G1 (CENP-F negative) and S/G2 (CENP-F positive) phase cells. Bars represent 
the mean of at least three independent experiments with > 40 cells counted per experiment. 
(Right) Selected images of cells showing Myc-GFP-STIL and pS1108 staining. Left images, 
scale bar, 5 μm.  Right images, scale bar, 0.5 µm. 
(I) Quantification showing the relative levels of pS1108/STIL at the centrosome of G1 or S/G2 





Figure 8. Phosphorylation of the STIL STAN domain is required for centriole duplication.   
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(A) Outline of the experimental timeline for the STIL siRNA and add-back experiments.  
(B) Immunoblot showing the relative STIL expression level after replacement of endogenous 
STIL with a Myc-GFP-STIL WT transgene.  
(C) Quantification showing the number of CEP192 foci in cells in which endogenous STIL had 
been depleted and replaced with the indicated Myc-GFP-STIL transgene. Bars represent the 
mean of at least three independent experiments with > 100 cells counted per experiment. 
(D-E) Quantification from (C) showing (D) the relative level of Myc-GFP-STIL at the 
centrosome of S/G2 phase cells and (E) the fraction of S/G2 phase cells with detectable Myc-
GFP-STIL at the centrosome. Bars represent the mean of at least three independent experiments 
with > 40 cells counted per experiment. 
(F) Quantification showing the number of CEP192 foci in cells in which endogenous STIL had 
been depleted and replaced with the indicated Myc-GFP-STIL transgene. ‘08A/16A’ refers to a 
Myc-GFP-STIL S1108A/S1116A double mutant. Bars represent the mean of at least three 
independent experiments with > 100 cells counted per experiment. The Myc-GFP-STIL 5A 
mutant from Figure 8C is shown alongside as a comparison. 
(G-H) Quantification from (F) showing (G) the relative level of Myc-GFP-STIL at the 
centrosome of S/G2 phase cells and (H) the fraction of S/G2 phase cells with detectable cells 
Myc-GFP-STIL at the centrosome. Bars represent the mean of at least three independent 
experiments with > 40 cells counted per experiment. The Myc-GFP-STIL 5A mutant from 
Figure 8D,E is shown alongside as a comparison. 
(I) Endogenous STIL was replaced with Myc-GFP-STIL WT, ∆STAN or S1116A. Graph shows 
the fluorescence recovery of centrosomal Myc-GFP-STIL after photobleaching. Points represent 
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Figure 9. STIL STAN domain phosphorylation is required for direct binding to SAS6. 
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(A-B) GST-STIL or GST-STIL C-term (a.a. 898-1287) was phosphorylated in vitro with kinase 
active or inactive His-PLK4 and incubated with SAS6. GST pull-downs were analyzed by 
immunoblot with the indicated antibodies. Graph shows the quantification from (B) of the 
relative amount of SAS6 bound to GST-STIL C-term. Bars represent the mean of three 
independent experiments.  
(C) (Top) Cells were co-transfected and subject to co-immunoprecipitation analysis with the 
indicated antibodies. (Bottom) Quantification of the relative amount of SAS6 bound to Myc-
GFP-STIL. Bars represent the mean of three independent experiments.  
(D-E) Quantification showing the relative level of PLK4 or SAS6 at the centrosome of cells in 
which endogenous STIL had been depleted and replaced with the indicated Myc-GFP-STIL 
transgene. Bars represent the mean of at least three independent experiments with > 50 cells 
counted per experiment. 
(F) Selected images of cells showing Myc-GFP-STIL and SAS6 staining. Left images, scale bar, 




Figure 10. The C-terminal domain of SAS6 interacts with STIL. 
(A) Cells were co-transfected with the indicated constructs and subject to co-
immunoprecipitation analysis with the indicated antibodies. 
(B) Immunoblot showing the levels of the indicated proteins at 48 hours after STIL siRNA.  
(C) Quantitative immunofluorescence analysis of the levels of STIL at the centrosome in 
different cell cycle phases. Bars show the mean of > 85 cells from at least two independent 




Figure 11. A model for how PLK4 and STIL cooperate to promote centriole assembly. 
(I) We propose that cytoplasmic STIL exists in an auto-inhibited conformation that prevents 
recruitment to the centriole. (II) PLK4 directly binds to STIL and this binding leads to activation 
of kinase activity through self-phosphorylation of the PLK4 activation loop. PLK4 then directly 
phosphorylates two sites in the STAN domain of STIL. (III) Phosphorylation of these sites 
releases STIL auto-inhibition to promote efficient centriole targeting. (IV) In a second step, STIL 
STAN domain phosphorylation promotes the binding of centriolar STIL to the C-terminal region 
of SAS6. We propose that binding of STIL to SAS6 triggers cartwheel assembly and the stable 




Chapter 3. PLK4 Phosphorylates STIL to 





Centrioles are microtubule-based structures that recruit a surrounding pericentriolar material 
(PCM) to form the centrosome (Nigg and Holland 2018; Gönczy 2012).  Centrosomes nucleate 
the formation of the microtubule cytoskeleton in interphase cells and form the poles of the 
mitotic spindle during cell division. In quiescent cells, centrioles dock at the plasma membrane 
and act as basal bodies that template the formation of cilia and flagella (Breslow and Holland 
2019). Cycling cells tightly couple centriole biogenesis with cell cycle progression. Centriole 
duplication begins at the G1-S phase transition when a new procentriole grows perpendicularly 
from a single site at the proximal end of each of the two parent centrioles. In late G2 phase, the 
two centriole pairs separate and increase PCM recruitment to promote the formation of the 
mitotic spindle. At the end of mitosis, the centrosomes are equally partitioned so that each 
daughter cell inherits a pair of centrioles. Defects in centriole biogenesis can result in the 
formation of supernumerary centrosomes which promote mitotic errors that can contribute to 
tumorigenesis (Levine et al. 2017; Levine and Holland 2018; Basto et al. 2008; Serçin et al. 
2016; Coelho et al. 2015). Moreover, mutations in centriole proteins are linked to growth 
retardation syndromes and autosomal recessive primary microcephaly (MPCH) in human 
patients (Nigg and Raff 2009; Gergely 2014). 
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The initiation of centriole duplication requires a conserved set of five core proteins: PLK4, 
CEP192, CPAP (also known as CENPJ), STIL, and SAS6 (Leidel and Gönczy 2003; Leidel et al. 
2005; Dammermann et al. 2004; Delattre et al. 2004; Kemp et al. 2004; O’Connell et al. 2001; 
Pelletier et al. 2004; Kirkham et al. 2003). Of these components, PLK4 has been identified as the 
central regulator of centriole assembly (Habedanck et al. 2005; Bettencourt-Dias et al. 2005). In 
mammalian cells, PLK4 is recruited to the centriole during G1 phase through binding to its 
centriole receptors CEP152 and CEP192, which encircle the proximal end of the parent centriole 
(Cizmecioglu et al. 2010; Hatch et al. 2010; T.-S. Kim et al. 2013; Park et al. 2014; K. F. Sonnen 
et al. 2013). At G1-S transition, PLK4 transforms from a ring-like localization to a single focus 
on the wall of the parent centriole that marks the site of procentriole formation (T.-S. Kim et al. 
2013; Ohta et al. 2014; Katharina F. Sonnen et al. 2012; Dzhindzhev et al. 2017). This transition 
bears features of a symmetry breaking reaction and can be recreated in silico using two positive 
feedback loops that act on PLK4 (Goryachev and Leda 2017; Leda, Holland, and Goryachev 
2018). Binding of PLK4 to its centriole substrate STIL promotes activation of the kinase and is 
required for its ring-to-dot transformation (Moyer et al. 2015; Ohta et al. 2014; Lopes et al. 
2015). PLK4 phosphorylates STIL in a conserved STAN motif to promote the binding and 
recruitment of SAS6 (Ohta et al. 2014; Kratz et al. 2015; Moyer et al. 2015; Dzhindzhev et al. 
2014). SAS6 homo-oligomerizes to organize the central cartwheel, a stack of ring-like 
assemblies with nine-fold symmetry that provides the structural foundation for the procentriole ( 
Kitagawa et al. 2011; Van Breugel et al. 2011; van Breugel et al. 2014; Cottee et al. 2015; 
Guichard et al. 2017).   
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Following cartwheel assembly, the centriole protein CPAP plays a critical role in the formation 
and stabilization of the triplet microtubule blades that make up the procentriole wall. CPAP 
interacts with multiple centriole proteins including STIL (Cottee et al. 2013; Tang et al. 2011; 
Vulprecht et al. 2012), CEP152 (Cizmecioglu et al. 2010; Dzhindzhev et al. 2010), CEP120 (Y. 
N. Lin et al. 2013), CEP135 (Y. C. Lin et al. 2013), and Centrobin (Gudi et al. 2015). The C-
terminal TCP domain of CPAP directly binds to a highly conserved PRP motif in STIL (Cottee 
et al. 2013; Tang et al. 2011; Vulprecht et al. 2012), while the N-terminal domain of CPAP 
interacts with /-tubulin heterodimers (Sharma et al. 2016; Xiangdong Zheng et al. 2016; Hung 
2004). These interactions allow CPAP to act as a molecular link between the cartwheel and the 
triplet microtubule blades of the centriole wall. Importantly, an MCPH mutation in the CPAP 
TCP domain weakens the STIL-CPAP interaction, highlighting the importance of this complex 
in centriole assembly and function (Cottee et al. 2013; Tang et al. 2011; Bond et al. 2005). CPAP 
positively regulates centriolar microtubule growth and, consequently, overexpression of CPAP 
leads to the formation of overly long centrioles in human cells (Tang et al. 2009; Schmidt et al. 
2009; Kohlmaier et al. 2009). In addition to its role in controlling microtubule growth, CPAP 
also functions in recruiting PCM, either through the direct tethering of PCM proteins or by 
recruiting Plk1/Polo which is critical in promoting PCM assembly (X. Zheng et al. 2014; 
Gopalakrishnan et al. 2011; Chou et al. 2016; Novak et al. 2016).  
 
At present, the binding of SAS6 to the STAN motif of STIL is the only interaction known to be 
controlled by PLK4 kinase activity. While the regulation of this assembly step is conserved in 
humans and flies (Ohta et al. 2014; Dzhindzhev et al. 2014; Moyer et al. 2015; Kratz et al. 2015), 
it is unclear whether this takes place in C.elegans, where ZYG-1/PLK4 directly binds and 
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recruits SAS6 to promote cartwheel assembly (Lettman et al. 2013). Moreover, although 
phosphomimetic mutations in the crucial PLK4 phosphorylation sites in the STAN motif of STIL 
are functional, they cannot support centriole duplication in the absence of PLK4 kinase activity 
(M. Kim et al. 2016). This suggests that PLK4 must phosphorylate STIL, or other substrates, at 
additional sites to promote centriole assembly. Indeed, recent work in Drosophila identified 
additional PLK4 phosphorylation sites required for centriole biogenesis in the N-terminus of 
Ana2/STIL, but exactly how these phosphorylation events contribute to centriole formation 
remains unclear (Dzhindzhev et al. 2017; McLamarrah et al. 2018).  
 
In this chapter, we identify a conserved PLK4 phosphorylation site on STIL that promotes 
binding to CPAP in vitro and in vivo. This phospho-dependent binding interaction is conserved 
in flies and allows STIL to link the growing cartwheel to the outer microtubule wall of the 
centriole. Together, our findings offer insight into a novel step in centriole assembly that is 
regulated by PLK4 kinase activity. 
 
 
3.2 PLK4 phosphorylates STIL to promote CPAP binding. 
 
PLK4 phosphorylates conserved residues in the STIL STAN motif to promote binding to SAS6 
(Moyer et al. 2015; Ohta et al. 2014; Dzhindzhev et al. 2014). To determine whether 
phosphorylation of STIL by PLK4 might affect the interaction of STIL with other components of 
the centriole duplication machinery, we tested the ability of Myc-GFP-STIL to interact with its 
known centriolar binding partners in the presence of kinase active (PLK4
WT
) or kinase dead 
(PLK4
KD




 mutant that stabilizes the active kinase by preventing PLK4-induced 
autodestruction (Holland et al. 2010). Expression of kinase active PLK4
∆24
-mCherry increased 
the binding of STIL to SAS6 in cells (Figure 12A), but did not increase binding to the STIL-
interacting partners RTTN (Chen et al. 2017) or CEP85 (Liu et al. 2018) (Figure 12B,C). 
Unexpectedly, we observed that PLK4 kinase activity promoted a robust increase in STIL 
binding to CPAP, suggesting that PLK4 kinase activity also controls the interaction of CPAP 
with STIL (Figure 12D).   
 
To determine how PLK4 phosphorylation promotes binding of CPAP to STIL, we mapped in 
vitro PLK4 phosphorylation sites on STIL using mass spectrometry. Recombinant full-length 
GST-STIL was phosphorylated with the His-PLK4 kinase domain in vitro. Of the 89 in vitro 
phosphorylation sites we identified on STIL, S428 was of particular interest as it is highly 
conserved, matches the PLK4 consensus phosphorylation sequence and is positioned close to the 
known CPAP binding region on STIL (Figure 13, Figure 14A) (Cottee et al. 2013; Kettenbach 
et al. 2012; Johnson et al. 2007; Hatzopoulos et al. 2013). To determine if phosphorylation of 
STIL S428 was responsible for enhancing the binding of CPAP to STIL, we co-expressed 
FLAG-CPAP and a wild type (WT) or S428A mutant of Myc-GFP-STIL in the presence of 
kinase active or inactive PLK4
∆24
-mCherry. The expression of kinase active PLK4 promoted a > 
7-fold increase in the amount of CPAP bound to WT STIL, but this increased binding was not 
observed with STIL S428A (Figure 14B). To test if this phospho-regulated binding interaction 
can be reconstituted with purified components, we performed GST-pull down experiments on 
recombinant WT or S428A GST-STIL that had been phosphorylated with the His-PLK4 kinase 
domain and then incubated with a recombinant Flag-CPAP TCP domain. Phosphorylation of WT 
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GST-STIL with PLK4 increased binding to the Flag-TCP domain by ~2.5-fold, but this 
increased binding was not observed with STIL S428A (Figure 14C). The use of the CPAP TCP 
domain rather than full-length protein may explain the more modest increase in CPAP binding to 
STIL in vitro compared to in vivo. These data show that phosphorylation of STIL S428 promotes 
CPAP binding to STIL in vitro and in vivo. 
 
To demonstrate STIL S428 is a bona fide PLK4 phosphorylation site, we raised a phospho-
specific antibody to this site. The affinity-purified pS428 antibody recognized recombinant GST-
STIL in the presence of ATP and the His-PLK4 kinase domain, but not in the absence of ATP 
(Figure 14D). Moreover, recognition of phosphorylated GST-STIL by the pS428 antibody was 
abolished by the S428A mutation, demonstrating the specificity of the pS428 antibody (Figure 
14D). To determine if PLK4 can phosphorylate STIL S428 in cells, we co-expressed WT or a 
S428A mutant of Myc-GFP-STIL with kinase active or inactive PLK4
∆24
-mCherry (Figure 
14E). The pS428 antibody recognized WT STIL in the presence of kinase active, but not kinase 
inactive, PLK4, showing that PLK4 phosphorylates STIL at S428 in vitro and in vivo. 
 
3.3 The phosphorylation-dependent binding of CPAP to STIL is conserved in 
flies. 
 
D.melanogaster PLK4 (DmPLK4) was recently shown to phosphorylate the STIL homolog Ana2 
at S38, a residue equivalent to S428 in the human STIL (McLamarrah et al. 2018; Dzhindzhev et 
al. 2017) (Figure 14A). Phosphorylation of S38 was shown to be required for Ana2 recruitment 
(Dzhindzhev et al. 2017) but was reported not to alter Ana2 binding to the CPAP orthologue 
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DmSas4 (McLamarrah et al. 2018). We reasoned that this discrepancy might arise because PLK4 
is a low-abundance protein that is activated at the centriole and is unable to efficiently 
phosphorylate a significant fraction of the transfected Ana2. To test this possibility, we 
transfected D.melanogaster S2 cells with either WT or S38A Myc-GFP-Ana2 and Flag-DmSas4 
in the presence or absence of a stabilized version of DmPLK4
SBM
-mCherry (Rogers et al. 2009). 
DmPLK4 promoted a > 6-fold increase in the amount of DmSas4 bound to WT Ana2, but this 
increased binding was not observed with Ana2 S38A (Figure 14F). These data suggest that the 
increased binding of CPAP/DmSas4 to phosphorylated STIL/Ana2 is conserved between human 
and flies. 
 
3.4 PLK4 phosphorylates STIL S428 to promote centriole duplication. 
 
To test the requirement of STIL S428 phosphorylation by PLK4 for centriole biogenesis, we 
integrated doxycycline-inducible, siRNA-resistant WT or S428A Myc-GFP-STIL transgenes a 
pre-defined genomic locus in a DLD-1 host cell line. As a control, we also generated DLD-1 
cells expressing a Myc-GFP-STIL S1116A transgene, which contains a mutation at a conserved 
PLK4 phosphorylation site in the STIL STAN motif required for efficient binding to SAS6 
(Moyer et al. 2015; Dzhindzhev et al. 2014; Ohta et al. 2014).  WT, S1116A and S428A Myc-
GFP-STIL transgenes were all expressed to similar levels in cells (Figure 16A, B). Depletion of 
STIL by siRNA resulted in 100% of mitotic cells with ≤ 2 centrioles, and this effect was almost 
completely rescued by expression of the WT STIL transgene (Figure 15A). By contrast, 
expression of either STIL S428A or S1116A only led to a partial rescue of centriole duplication 
(61% S428A cells and 70% S1116A cells contain ≤ 2 centrioles in mitosis) (Figure 15A). 
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Importantly, preventing S428 phosphorylation did not affect the ability of STIL to bind to or 
stimulate PLK4 kinase activity, suggesting that a failure to activate PLK4 kinase activity is not 
responsible for the failure of centriole duplication (Figure 17A) (Moyer et al. 2015).  These data 
show that phosphorylation of STIL S428 by PLK4 promotes centriole duplication. 
 
3.5 Preventing STIL S428 phosphorylation phenocopies mutations in the 
CPAP binding motif of STIL. 
 
CPAP interacts with STIL via a short proline-rich region containing a highly conserved 
PRxxPxP motif (Figure 14A) (Cottee et al. 2013). To test whether defective CPAP binding 
causes the failure to rescue centriole duplication with STIL S428A, we created a PRP mutant of 
STIL by mutating the conserved PRPIPSP CPAP binding motif to AAPIASP (P404A, R405A, 
P408A). This mutation did not affect PLK4’s ability to phosphorylate STIL on S428 (Figure 
17B). As expected, the STIL PRP mutant showed impaired binding to CPAP (Figure 15E).  
Expression of Myc-GFP-STIL PRP led to only a partial rescue of centriole duplication in cells 
depleted of endogenous STIL by siRNA, similar to that of the STIL S428A mutation (Figure 
15A). Combining the S428A or PRP mutation with the S1116A mutation in the STIL STAN 
motif that impairs binding to SAS6 prevented any rescue of centriole duplication (Figure 
15A,B). By contrast, a Myc-GFP-STIL transgene containing both the S428A and PRP mutation 
rescued centriole duplication to a level similar to that observed with a STIL transgene that 
contained either mutation on its own (Figure 15A,B). Collectively, these data suggest that S428 
phosphorylation and the PRxxPxP motif of STIL function in the same pathway to promote CPAP 
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binding to STIL, and that they both are in a separate pathway from mutations that disrupt SAS6 
binding to STIL. 
 
To evaluate the impact of disrupting CPAP and SAS6 binding on the centriole targeting of STIL, 
we measured the levels of Myc-GFP-STIL transgenes at the centriole in S/G2 phase cells 
depleted of endogenous STIL. Preventing phosphorylation at S428 reduced the localization of 
Myc-GFP-STIL by 28%, compared to that of the WT transgene (Figure 15C,D).  Preventing 
phosphorylation at S1116 in the STAN motif reduced the abundance of STIL at the centriole by 
~2-fold, as previously reported (Figure 15C) (Moyer et al. 2015).  However, preventing 
phosphorylation of both sites reduced the centriole localization of STIL by 80%, suggesting that 
stable incorporation of STIL into the centriole requires strong binding to both CPAP and SAS6 
(Figure 15B,C,D, Figure 18). Combining the S428A and PRP mutations did not diminish the 
levels of centriolar STIL below that observed with either mutation alone (Figure 15C). This 
provides further evidence that the S428A and PRP mutations function in the same pathway and 
act to reduce the stability of CPAP binding to STIL. 
 
3.6 Phosphorylation of the STIL STAN motif by PLK4 does not require STIL 
S428 phosphorylation.  
 
Experiments in flies suggested that DmPLK4 phosphorylates S38 to promote Ana2 recruitment 
to the centriole and then phosphorylates conserved residues in the STAN motif to enable SAS6 
recruitment (Dzhindzhev et al. 2017; McLamarrah et al. 2018). However, we found that 
phosphorylation of STIL S428 in human cells does not play a significant role in the centriolar 
 54 
recruitment of STIL (Figure 15C,D). To determine whether phosphorylation of the STAN motif 
requires phosphorylation of STIL S428, or vice versa, we monitored phosphorylation of STIL 
S428 and S1116 using phospho-specific antibodies. Expression of kinase active PLK4
∆24
-
mCherry promoted phosphorylation of a Myc-GFP-STIL transgene at both S428 and S1116, and 
mutation of either site did not prevent phosphorylation of the other (Figure 19). To test if PLK4-
mediated phosphorylation of the STIL STAN motif at the centriole requires phosphorylation of 
S428, we monitored phosphorylation of S1108 in the STAN motif using a phospho-specific 
antibody (Moyer et al. 2015). Although treatment with the PLK4 inhibitor centrinone abolished 
STIL S1108 phosphorylation, the S428A or PRP motif mutation did not affect phosphorylation 
of STIL S1108 (Figure 19). These data show that phosphorylation of the STIL STAN motif by 
PLK4 does not require prior phosphorylation of STIL S428. 
 
3.7 Stable centriole recruitment of STIL requires STIL S428 phosphorylation. 
 
To examine how S428 phosphorylation affects the binding dynamics of centriolar STIL, we 
performed Fluorescence Recovery after Photobleaching (FRAP) in cells depleted of endogenous 
STIL and expressing Myc-GFP-STIL transgenes.  Myc-GFP-STIL WT partially recovered 
following bleaching, showing that STIL exists in both mobile and immobile pool at the 
procentriole (Figure 20A, Myc-GFP-STIL WT, recovery percentage (R%) = 38%). Consistent 
with previous observations, mutation of the S1116 phosphorylation site increased the mobile 
fraction of centriolar STIL (Figure 20A, Myc-GFP-STIL S1116A, R% = 71%) (Moyer et al. 
2015). Importantly, the S428A and PRP mutants of STIL also showed an increased recovery of 
centriolar STIL (Figure 20A, Figure 21); Myc-GFP-STIL S428A, R% = 57%; Myc-GFP-STIL 
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PRP, R% = 58%), suggesting that CPAP binding allows more stable incorporation of STIL into 
the procentriole.  
 
To understand how mutations in STIL affect centrosomal CPAP dynamics, we monitored 
centrosomal GFP-CPAP turnover using FRAP by knocking down endogenous CPAP and 
expressing a siRNA-resistant Myc-GFP-CPAP transgene.  As previously reported, Myc-GFP-
CPAP partially recovered after photobleaching (Figure 22A), Myc-GFP-CPAP, R% = 51%) (D. 
Kitagawa et al. 2011).  Surprisingly, performing the same measurements in cells depleted of 
STIL led to an almost complete turnover of Myc-GFP-CPAP (Figure 22A, Myc-GFP-CPAP, 
STIL siRNA, R% = 96%). While STIL is uniquely localized to the procentriole, CPAP is present 
at both the parent centriole and procentriole. In addition, CPAP has been reported to localize in 
the PCM material (Sonnen et al. 2012), consistent with a proposed role in recruiting PCM (X. 
Zheng et al. 2014; Gopalakrishnan et al. 2011; Chou et al. 2016; Novak et al. 2016). Since we 
bleach all of the pools of CPAP in our FRAP experiments, we cannot distinguish which 
centrosomal populations of CPAP are dynamic and which are stably bound. Nevertheless, given 
STIL localizes exclusively to the procentriole, one interpretation of our data is that STIL is 
required for the stable incorporation of CPAP at the procentriole, while the parental centriole and 
PCM pool of CPAP are dynamic and display a transient association with the centrosome. 
 
To test the role of STIL S428 phosphorylation in modulating CPAP turnover at the centrosome, 
we integrated into DLD1 cells a Myc-STIL-T2A-GFP-CPAP transgene in which siRNA-resistant 
Myc-STIL and GFP-CPAP were both expressed from the same doxycycline-inducible promoter. 
As expected, Myc-STIL expression significantly suppressed the increased turnover of GFP-
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CPAP observed in cells depleted of endogenous STIL (Figure 22A, GFP-CPAP, Myc-STIL WT 
background, R% = 50%).  However, mutation of S428 or the PRP motif on STIL increased the 
turnover of GFP-CPAP compared with WT STIL (Figure 20B, Figure 22B, GFP-CPAP, Myc-
STIL S428A background, R% = 69%; GFP-CPAP, Myc-STIL PRP background, R% = 67%).  
Expression of Myc-STIL S1116A did not increase GFP-CPAP turnover, indicating that the 
increase in GFP-CPAP turnover in a Myc-STIL S428A background reflects a specific defect in 
the STIL/CPAP interaction (Figure 20B, GFP-CPAP, Myc-STIL S1116A background, R% 
=55%). These data suggest that STIL binding allows a more stable incorporation of CPAP into 
the centrosome, possibly by facilitating interactions with CPAP at the procentriole. However, 
since the depletion of STIL resulted in a higher level of CPAP turnover than specifically 
disrupting the STIL/CPAP interaction, it is likely STIL recruits additional proteins that 
collectively act to stabilize the incorporation of CPAP into the centrosome. Together, our data 
show that the interaction of CPAP with STIL allows both proteins to incorporate more stably 
into the centrosome. 
 
3.8 Mutations in the CPAP TCP domain cause less stable CPAP incorporation 
into the centrosome.  
 
To better understand the requirement of the STIL/CPAP interaction in centriole duplication, we 
constructed an RNAi-replacement system in DLD-1 cells where endogenous CPAP was depleted 
by siRNA and replaced with physiological levels of a siRNA-resistant Myc-GFP-CPAP 
transgene (Figure 23A, Figure 23B). Knockdown of CPAP by siRNA resulted in 81% of mitotic 
cells with ≤ 2 centrioles, and this was largely rescued by expression of the CPAP WT transgene 
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(Figure 23C). By contrast, expression of a CPAP transgene with mutations in the TCP domain 
that reduced binding to STIL (F1229A or E1235K), led to a partial rescue of centriole 
duplication (58% of F1229A cells and 48% of E1235K cells contain ≤ 2 centrioles in mitosis) 
(Figure 23C, Figure 23D) (Cottee et al. 2013; Hatzopoulos et al. 2013). Importantly, the 
presence of these TCP domain mutations increased the turnover of Myc-GFP-CPAP at the 
centrosome (Figure 23E, Myc-GFP-CPAP R% = 51%; Myc-GFP-CPAP F1229A, R% = 76%; 
Myc-GFP-CPAP E1235K, R% = 67%), but did not alter the abundance of the Myc-GFP-CPAP 
or STIL at the centrosome (Figure 23F-H). Collectively, these data support the conclusion that 
the STIL-CPAP interaction facilitates the stable centrosomal integration of CPAP, but that this 
interaction does not have a major impact on the level to which CPAP accumulates at the 
centrosome. 
 
3.9 STIL depletion reduces the localization of CPAP to the centrosome.  
 
To further test whether the overall level of CPAP present at the centrosome depends on STIL, we 
measured centrosomal CPAP levels in S/G2 cells depleted of STIL by siRNA. STIL knockdown 
reduced the level of CPAP at the centrosome by ~30% (Figure 24A-C). Importantly, we 
observed that centrosomal CPAP levels were not significantly reduced following depletion of 
endogenous STIL and expression of a WT or mutant Myc-GFP-STIL transgene (Figure 24D,E). 
This is consistent with a model in which CPAP is localized to the parent centriole independently 
of STIL, while procentriole localized CPAP requires STIL for stable binding. However, our data 
argue that the role of STIL in recruiting CPAP to the centrosome is largely independent of the 
STIL/CPAP interaction and likely depends on the recruitment of other proteins. This is 
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consistent with our FRAP analysis which showed that depletion of STIL increased the turnover 
of CPAP at the centriole from 51% to 96%, while disruption of STIL binding to CPAP increased 
CPAP turnover to only ~70%. We conclude that the recruitment of the majority of CPAP present 
at the centrosome does not require CPAP binding to STIL. 
 
3.10 Recruitment of CPAP to de novo formed centrioles requires STIL S428 
phosphorylation.  
 
The multiple populations of CPAP present at the centrosome prevented us from specifically 
testing the requirement of STIL S428 phosphorylation for CPAP recruitment to the procentriole. 
To analyze the role of STIL S428 phosphorylation in recruiting CPAP specifically to assembling 
procentrioles, we induced the formation of freestanding de novo centrioles in cells expressing 
various STIL mutants. DLD-1 cells expressing a Myc-GFP-STIL transgene were chronically 
treated with the PLK4 inhibitor centrinone to remove centrioles (Wong et al. 2015). Acentriolar 
cell lines were then depleted of endogenous STIL by siRNA for twenty-four hours, and 
centrinone was removed to induce the formation of freestanding de novo centrioles (Figure 
25A). De novo centrioles were defined as foci marked by both PLK4 and Centrin (Figure 26). 
As expected, depletion of STIL suppressed de novo centriole assembly, and this was rescued by 
expression of a WT Myc-GFP-STIL transgene (48% and 87% of cells expressing WT STIL 
contained de novo centrioles at 24 and 72 hours after centrinone washout, respectively) (Figure 
25B). S428A, S1116A, and PRP Myc-GFP-STIL were all deficient in assembling de novo 
centrioles, with only 25%, 12%, and 33% of cells containing PLK4 and Centrin positive foci at 
72 hours after centrinone removal, respectively.  While cells expressing Myc-GFP-STIL S1116A 
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STIL formed very few STIL/PLK4 foci, the number of foci observed in cells expressing S428A 
and PRP Myc-GFP-STIL was comparable to that observed with the WT STIL transgene (Figure 
25C, Figure 26). This suggests that cells which express the S428A and PRP mutant STIL fail 
centriole assembly at a later stage than those that cells express the S1116A mutant of STIL.  
 
To determine why the S428A and PRP mutations fail de novo centriole formation after forming 
STIL/PLK4 foci, we measured the recruitment of SAS6 and CPAP to the newly formed STIL 
foci. WT Myc-GFP-STIL recruited both CPAP and SAS6 to as expected (Figure 25D-H). While 
recruitment of SAS6 was identical in WT, S428A and PRP Myc-GFP-STIL, the S428A and PRP 
mutations resulted in a > 90% reduction in the amount of CPAP recruitment to the STIL foci 
(Figure 25D-H).  Together, these data suggest that S428A and PRP mutant STIL bind to SAS6 




Significant progress has been made in understanding the composition of centrioles and how 
protein interactions can direct centriole assembly (Andersen et al. 2003; Jakobsen et al. 2011; 
Firat-Karalar et al. 2014; Galletta et al. 2016; Gupta et al. 2015). However, we have a limited 
understanding of which assembly steps are controlled by PLK4 to maintain the number of 
centrioles in cycling cells. Our data now establish that PLK4 phosphorylates its centriole 
substrate STIL on a conserved site close to the PRP motif to promote STIL binding to CPAP in 
vitro and in vivo. The STIL/CPAP complex is only the second binding interaction shown to be 
controlled by PLK4 and highlights a new regulated step in centriole assembly. 
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Our data lead us to propose a model whereby active PLK4 phosphorylates STIL at the site of 
procentriole assembly in two different regions with distinct functional consequences (Figure 7): 
phosphorylation of multiple residues in the STAN motif, most notably S1116, allows STIL 
binding to SAS6 to promote cartwheel assembly. Second, phosphorylation of S428 promotes the 
binding of the STIL PRP motif to CPAP, thereby linking the growing cartwheel to the triplet 
microtubules of the centriole wall. This model is consistent with our analysis of de novo centriole 
assembly, which showed that phosphorylation of the STIL STAN motif is required to recruit 
SAS6 to the site of procentriole assembly while phosphorylation of STIL S428 is required at a 
later stage to recruit CPAP to the cartwheel. Moreover, super-resolution imaging of Drosophila 
centrioles has revealed that the C-terminal region of Ana2/STIL containing the STAN motif is 
located closer to the cartwheel hub, while the N-terminal region containing the PRP motif is 
positioned close to the C-terminus of Sas-4/CPAP at the periphery of the cartwheel (Gartenmann 
et al. 2017). A mutation in the CPAP TCP domain that causes microcephaly in humans has been 
shown to decrease the affinity of CPAP to STIL (Tang et al. 2011; Cottee et al. 2013; Bond et al. 
2005). Moreover, mutations in STIL that reside in the CPAP and SAS6 interacting motifs have 
also been identified in patients with microcephaly, although the significance of these alterations 
remains to be determined (Cristofoli et al. 2017).   
 
Although recruitment of CPAP to assembling de novo centrioles requires STIL S428 
phosphorylation, this modification is not required for recruiting the bulk of CPAP to the 
centrosome. We envisage two possible explanations for these observations. First, although 
sharing obvious similarities, de novo centriole assembly may have some distinct requirements 
compared with canonical centriole biogenesis. For example, the presence of a parent centriole 
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may help direct CPAP recruitment to the site of procentriole assembly; CPAP localized in the 
PCM could be recruited to the procentriole by some of CPAP’s other interacting partners in the 
absence of STIL S428 phosphorylation. A second possibility is that multiple pools of CPAP at 
the centrosome (parent centriole, procentriole and PCM associated) may obscure the ability to 
accurately monitor the role of STIL phosphorylation in CPAP recruitment at the nascent 
procentriole. In any case, it is clear that even if the STIL-CPAP interaction is not strictly 
necessary for the recruitment of either protein to canonically duplicating centrioles, it does allow 
for the more stable integration of these proteins into the centrosome.   
 
A previous study solved the structure of the CPAP TCP domain bound to a short STIL peptide 
(residues 395 - 416) containing the PRP motif but lacking the S428 phosphorylation site (Cottee 
et al. 2013). A central question that now emerges is how phosphorylation of S428, which is 
positioned ~20 amino acids downstream of the core PRP interaction motif in STIL, promotes 
binding to CPAP in cells. We envisage two non-mutually exclusive possibilities. First, 
phosphorylation creates an extended binding interface that increases the affinity of STIL to 
CPAP. Indeed, sequence conservation in the CPAP TCP domain is not confined to the region 
that directly interacts with the PRP motif of STIL but extends further along the surface of the 
TCP domain beta sheet, suggesting that additional contacts with STIL may occur in this region 
(Cottee et al. 2013). Moreover, there is high conservation around the S428 phosphorylation site 
on STIL, and this conserved motif was proposed to be well positioned to form an extended 
interaction interface with conserved residues in the CPAP TCP domain (Cottee et al. 2013). 
Phosphorylation of STIL S428 could, therefore, seed the binding of this conserved region and 
cooperatively enhance the binding of STIL to CPAP. 
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An alternative hypothesis is that S428 phosphorylation generates a conformational change that 
unmasks the PRP motif in STIL and exposes it for binding to CPAP. In support of this model, 
work in Drosophila has shown that phosphorylation of the homologous site (S38) on Ana2/STIL 
leads to a dramatic mobility shift in an SDS page gel that is likely to reflect a significant 
conformational change in Ana2 (Dzhindzhev et al. 2017). It is notable that C.elegans SAS-
5/STIL lacks an obvious PRP motif, but directly binds to SAS-4/CPAP through a disordered 
region (Cottee et al. 2013). Moreover, the SAS-4/CPAP TCP domain is required for the 
incorporation of SAS-4 into the centriole in C.elegans. SAS-5 has also been shown to bind to 
microtubules through a region that overlaps with the SAS-4 binding domain, suggesting that the 
interaction of SAS-5 with microtubules and SAS-4 may be mutually exclusive (Rothbauer et al. 
2007). In the future, it will be interesting to investigate if ZYG-1/PLK4 kinase activity regulates 
the critical SAS-5/SAS-4 interaction in C.elegans and switches SAS-5 from binding 
microtubules to an association with SAS-4.  
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3.12 Figures and Legends 
 
 
Figure 12. PLK4 kinase activity promotes STIL binding to CPAP.   
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(A-D) HEK293FT cells were transfected with indicated constructs, subjected to co-
immunoprecipitation and immunoblotted with indicated antibodies. PLK4 activity increased 
binding of both SAS6 and CPAP to STIL.  
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Figure 13. In vitro PLK4 phosphorylation sites on STIL.   
 66 
Recombinant GST-STIL was phosphorylated by PLK4 kinase domain in vitro, and 
phosphorylation sites were mapped with mass spectrometry.  Phosphorylated residues were 
scored as to whether or not they are conserved (see Figure 14A for sample alignment) and 






Figure 14. Phosphorylation of STIL by PLK4 promotes increased CPAP binding. 
(A) Schematic of full-length STIL showing locations of the known CPAP binding motif, coiled-
coil (CC), and STAN motif important for SAS6 binding. Sequence alignment shows the 
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conserved CPAP binding motif.  The fragment of STIL crystalized with CPAP is shown by the 
grey bar.  STIL residues key to the STIL-CPAP interaction (P404, R405, and P408) are 
highlighted. The conserved PRxxPxP motif is indicated in red. Alignment was generated using 
Muscle under standard parameters.  
(B) HEK293FT cells were transfected with indicated constructs, subjected to co-
immunoprecipitation and immunoblotted with indicated antibodies.  The graph represents the 
mean of relative levels of immunoprecipitated Flag/Myc signal across three independent 
experiments. A dot displays measurements from each experiment. (C) Recombinant full-length 
GST-STIL (WT or S428A) was bound to beads, phosphorylated by recombinant 6xHis-PLK4 
kinase domain, and then incubated with Flag-CPAP TCP domain. GST-pulldowns were analyzed 
by immunoblotting with indicated antibodies. The graph represents the mean of relative levels of 
Flag-TCP pulled down with GST-STIL. A dot displays measurements from each experiment. (D) 
Recombinant full-length GST-STIL (WT or S428A) was phosphorylated in vitro by recombinant 
6xHis-PLK4 kinase domain. Samples were immunoblotted with indicated antibodies. CBB 
represents ‘coomassie brilliant blue’ staining and shows the recombinant PLK4 kinase domain.   
(E) HEK293FT cells were transfected with indicated constructs and immunoblotted with 
indicated antibodies.  
(F) Drosophila melanogaster S2 cells were transfected with indicated constructs, subjected to 
co-immunoprecipitation and immunoblotted with indicated antibodies.  The graph represents the 
mean of relative levels of immunoprecipitated Flag/Myc signal across three independent 
experiments.  A dot displays measurements from each experiment. All error bars in the figure 
represent the standard error of the mean.  Asterisks indicate statistically significant differences 
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between measurements (*: P<0.05; **: P<0.005; ***: P<0.0005).  Statistics were calculated 







Figure 15. STIL S428 phosphorylation promotes centriole duplication. 
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(A) Quantification showing the number of mitotic Centrin foci in cells that were depleted of 
endogenous STIL and induced to express a siRNA-resistant Myc-GFP-STIL transgene as 
indicated.  Representative images show mitotic cells. Scale bars represent 5 µm.  
(B) The table shows abbreviations for Myc-GFP-STIL transgenes with multiple mutations.  
‘PRP’ represents a triple mutation of P404A, R405A, and P408A.   
(C) Quantification of the relative centrosomal levels of Myc-GFP-STIL constructs from (A) in 
S/G2 phase cells with at least 40 cells measured per experiment. Bars represent the mean of at 
least three independent experiments with the average within each experiment shown as a dot.  
(D) Representative images of data shown in (C). Scale bar represents 5 µm.  All error bars in the 
figure represent the standard error of the mean. 
(E) HEK293FT cells were transfected with indicated constructs and subjected to co-
immunoprecipitation and immunoblotted with indicated antibodies. Graph represents the mean 
of relative levels of immunoprecipitated Flag/Myc signal across three independent experiments. 






Figure 16. STIL transgenes are expressed to similar levels. 
 (A) Experimental outline for the STIL RNAi-replacement experiments.  
(B) Immunoblot showing Myc-GFP-STIL transgene expression levels after knockdown of 







Figure 17. STIL PRP mutations do not affect S428 phosphorylation. 
 
HEK293FT cells were transfected with indicated constructs, subjected to co-
immunoprecipitation and immunoblotted with indicated antibodies. (A) Both WT and S428A 
STIL are capable of activating PLK4 and increasing autophosphorylation of T170. (B) The STIL 







Figure 18. Preventing STIL phosphorylation inhibits accumulation of STIL at the 
centriole. 
Representative images of data shown in (Figure 15C). Scale bar represents 5 µm.  All error bars 









Figure 19. Phosphorylation of the STIL STAN motif by PLK4 does not require STIL S428 
phosphorylation. 
(A) HEK293FT cells were transfected with indicated constructs, subjected to co-
immunoprecipitation and immunoblotted with indicated antibodies.  Preventing phosphorylation 
of STIL S428 does not block STIL S1116 phosphorylation, and vice-versa.  
(B) Endogenous STIL was knocked down and replaced with indicated Myc-GFP-STIL 
transgene. Where indicated, cells were treated with centrinone for 1 hour. Left, representative 
images showing Myc-GFP-STIL and pS1108 staining. Scale bar represents 5 µm. Right, 
quantification of the relative centrosomal ratio of pS1108/GFP-STIL in S/G2 phase cells. Bars 
represent the mean of three independent experiments in which at least 40 cells were quantified 
per experiment, and the average within each experiment is shown as a dot. Error bars represent 









Figure 20. STIL S428 phosphorylation promotes the stable integration of CPAP into the 
centrosome. 
(A) Cells were depleted of endogenous STIL and replaced with the indicated transgene. Myc-
GFP-STIL centrosomal foci were photobleached, and fluorescence recovery was measured. The 
number of quantified photobleaching and recovery events are indicated. Representative 
timepoints are shown below.  
(B) Cells were depleted of endogenous STIL and CPAP and replaced with indicated Myc-STIL-
T2A-GFP-CPAP transgene. GFP-CPAP centrosomal foci were photobleached, and fluorescence 
recovery was measured. The number of quantified photobleaching events is indicated.  
Representative timepoints are shown below. All error bars in the figure represent the standard 
error of the mean. Asterisks indicate statistically significant differences between measurements 
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(*: P<0.05; **: P<0.005; ***: P<0.0005).  Statistics were calculated using an unpaired t-test 
against the population of recovery measurements between indicated samples at the 360 second 






Figure 21. The STIL PRP mutation mimics the turnover dynamics of the STIL S428A 
mutation. 
(A) Cells were depleted of endogenous STIL and replaced with the indicated transgene. Myc-
GFP-STIL centrosomal foci were photobleached, and fluorescence recovery was measured. The 
number of quantified photobleaching and recovery events is indicated.  Representative 
timepoints are shown below. Note that ‘WT’ and ‘S428A’ recovery traces are repeated from 













Figure 22. Centrosomal CPAP turns over in response to STIL depletion. 
(A) (WT, grey) Cells were depleted of endogenous CPAP and replaced with a Myc-GFP-CPAP 
transgene. (WT, STIL siRNA) Cells were depleted of endogenous CPAP and STIL, and CPAP 
was replaced with a Myc-GFP-CPAP transgene. (WT, Myc-STIL background)  
(B) Cells were depleted of endogenous STIL and CPAP with replaced with a Myc-STIL-T2A-
GFP-CPAP transgene. Centrosomal GFP-CPAP foci were photobleached, and fluorescence 
recovery was measured. The number of quantified photobleaching and recovery events is 
indicated. Representative timepoints are shown below. Note that ‘WT’ and ‘S428A/ (Myc-STIL 
background)’ traces are repeated from Figure 20B. 
 80 
 
Figure 23. Mutations in the CPAP TCP domain cause less stable CPAP incorporation into 
the centrosome. 
(A) Experimental outline for the STIL RNAi-replacement experiments. 
 81 
(B) Immunoblot showing the Myc-GFP-CPAP transgene expression levels after knockdown of 
endogenous CPAP. Note that a background band (denoted by a red asterisk) appears in control 
lanes that overlaps with the Myc-GFP-CPAP transgene.   
(C) Quantification showing the number of mitotic Centrin foci in which cells were depleted of 
endogenous CPAP and induced to express a siRNA-resistant Myc-GFP-CPAP transgene as 
indicated. 
(D) HEK293FT cells were transfected with indicated constructs, subjected to co-
immunoprecipitation and immunoblotted with indicated antibodies. Graph represents the mean 
of relative levels of immunoprecipitated Flag/Myc signal across three independent experiments. 
A dot indicates the average within each experiment.  
(E) Cells were depleted of endogenous CPAP and replaced with indicated transgene. Myc-GFP-
CPAP centrosomal foci were photobleached, and fluorescence recovery was measured. The 
number of quantified photobleaching and recovery events is indicated.  Representative 
timepoints are shown below. Note that ‘WT’ trace is repeated from Figure 22. 
(F) Quantification of the relative centrosomal levels of Myc-GFP-CPAP from S/G2 phase cells 
with at least 40 cells measured per experiment. Bars represent the mean of at least three 
independent experiments with the average within each experiment shown as a dot. 
(G) Quantification of the relative centrosomal levels of STIL from S/G2 phase cells with at least 
40 cells measured per experiment. Bars represent the mean of at least three independent 
experiments with the average within each experiment shown as a dot.  (H) Representative images 
from data quantified in (F) and (G). Scale bar represents 5 µm.  All error bars represent the 





Figure 24. Centrosomal CPAP localization does not depend on the STIL-CPAP interaction. 
(A) Quantification of the relative centrosomal levels of endogenous STIL in S/G2 phase cells 48 
hours after STIL siRNA.  Bars represent the mean of three independent experiments in which at 
least 40 cells were quantified per experiment, and the average within each experiment is shown 
as a dot.  
(B) Quantification of the relative centrosomal levels of CPAP in S/G2 phase cells 48 hours after 
STIL siRNA.  Bars represent the mean of three independent experiments in which at least 40 
cells were quantified per experiment, and the average within each experiment is shown as a dot.   
(C) Representative images from the quantification shown in (A) and (B).   
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(D) Quantification of the relative centrosomal levels of CPAP from experiment described in 
Figure 15A-C in S/G2 phase cells with at least 40 cells measured per experiment. Bars represent 
the mean of at least three independent experiments with the average within each experiment 
shown as a dot.  
(E) Representative images of data shown in (D). Scale bar represents 5 µm.  All error bars 






Figure 25. STIL S428 phosphorylation is required for recruitment of CPAP to de novo 
centrioles. 
(A) Experimental outline for de novo centriole assembly assay.  DLD-1 cells were maintained in 
500 nM centrinone for seven or more days to deplete centrioles, and then endogenous STIL was 
knocked down with siRNA.  Twenty-four hours later, centrinone was washed out, and the 
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expression of a siRNA-resistant Myc-GFP-STIL transgene was induced with doxycycline.  Cells 
were analyzed at 24, 48, and 72 hours post-centrinone washout.  
(B) Quantification showing the number of Centrin foci in interphase cells under the indicated 
conditions.  Bars represent the mean of three independent experiments in which at least 40 cells 
were counted per condition.  ‘Post-wo’ refers to post-washout. A Centrin focus was counted as a 
de novo centriole if it overlapped with a PLK4 focus (see Figure 26).   
(C) Quantification showing the number of Myc-GFP-STIL foci, or endogenous STIL foci in 
parental line, in cells under the indicated conditions. ‘Post-wo’ refers to post-washout. Bars 
represent the mean of three independent experiments in which at least 40 cells were counted per 
condition.  
(D) Representative images of de novo centriole formation showing CPAP localization. Cells 
were fixed at 24 hours post-centrinone washout. Scale bar represents 5 µm.  
(E) Representative images of de novo centriole formation showing SAS6 localization. Cells were 
fixed at 24 hours post-centrinone washout. Scale bar represents 5 µm.  
(F-H) Quantification of the relative localization of (F) Myc-GPF-STIL, (G) CPAP, and (H) 
SAS6 at de novo centrioles. Bars represent the mean of three independent experiments in which 
at least 40 cells were quantified per mutant, and a dot indicates the average within each 




Figure 26. De novo centriole formation requires phosphorylation of STIL S428 and S1116 
by PLK4. 
Representative images of de novo centriole formation at 72 hours after centrinone washout.  






Figure 27. Model depicting the early stages of de novo centriole formation.  
PLK4 activity recruits STIL to a PLK4 focus and phosphorylates STIL at S1116 in the STAN 
motif to recruit SAS6 and initiate cartwheel assembly. Phosphorylation of STIL at S428 by 
PLK4 promotes CPAP binding and connects the growing cartwheel to the triplet microtubules of 
the centriole wall. In the absence of STIL S428 phosphorylation, STIL is able to recruit SAS6 
and promote cartwheel assembly. However, STIL S428A fails to recruit CPAP and link the 
cartwheel to the microtubule wall, leading to a failure of de novo centriole assembly.  In the 
absence of STIL S1116 phosphorylation, STIL is not effectively recruited to a PLK4 focus and 
cartwheel assembly fails.  All error bars represent the standard error of the mean. 
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Chapter 4. Materials and Methods 
 
Antibody production 
A C-terminal hPlk4 fragment (a.a. 510-970) was cloned into a pET-23b bacterial expression 
vector (Novagen) containing a C-terminal 6xHis tag. Recombinant protein was purified from E. 
coli using Ni–NTA beads (QIAGEN) and used for immunization (ProSci). A STIL C-terminal 
peptide VGTFLDVKRLRQLPKLF (a.a. 1271-1287) was synthesized and conjugated to KLH for 
immunization. Rabbit immune sera were affinity-purified using standard procedures. Affinity-
purified antibodies were directly conjugated to DyLight 550 and DyLight 650 fluorophores 
(Thermo Scientific) for use in immunofluorescence. 
Human Centrin2 (a.a. 1-172) was cloned into a pET-23b bacterial expression vector (Novagen) 
containing an N-terminal 6xHis-SUMO1 tag. Recombinant protein was purified from E. coli 
using Ni–NTA beads (BioRad), cleaved from beads with SUMO protease and used for 
immunization in rabbits (ProSci). An N-terminal CEP192 fragment (a.a. 1-211) was cloned into 
a pGEX GST bacterial expression vector containing an N-terminal GST tag. Recombinant 
protein was purified from E. coli using glutathione sepharose beads (GoldBio), cleaved from 
beads with PreScission protease (GE) and used for immunization in goats. Rabbit and goat 
immune sera were affinity-purified using standard procedures. Affinity-purified antibodies were 
directly conjugated to Alexa Fluor488, DyLight 550, or DyLight 647 fluorophores (Thermo 
Scientific) for use in immunofluorescence. 
 
A synthetic phospho-peptide based on the human hSTIL sequence flanking serine 1108 
[CDRSTVGL(pS)LISPN], 1116 [CSPNNM(pS)FATKK] , or 428 [CSVPEL(pS)LVDG] was 
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synthesized, coupled to KLH and injected into rabbits (ProSci). Polyclonal pS1108, pS1116, and 
pS428 antibodies were affinity-purified using the appropriate phosphopeptide coupled to a 
SulfoLink Coupling Resin (Thermo Scientific). Additionally, a synthetic phospho-peptide based 
on the human PLK4 sequence flanking threonine 170 [HEKHY(pT)LCGTC] was synthesized, 
coupled to KLH and injected into rabbits (ProSci). Polyclonal pT170 antibodies were affinity-
purified using the human PLK4 phosphopeptide coupled to a SulfoLink Coupling Resin (Thermo 
Scientific).  
 
Cell culture and drug treatments 
Cells were maintained at 37°C in a 5% CO2 atmosphere with 21% oxygen. Cells were grown in 
Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (Sigma) or 
10% FB Essence serum (VWR), 100 U/ml penicillin, 100 U/ml streptomycin and 2 mM L-














Core Kit (Life Technologies) to stably express the Tetracycline repressor protein and contain a 
single, genomic FRT/lacZeo site. 3MB-PP1 (Sigma) was dissolved in DMSO and used at a final 
concentration of 10 µM unless otherwise stated. Centrinone (a kind gift from Karen Oegema) 






Gene targeting  




-DLD-1 cells using CRISPR/Cas9. Briefly, a 
gRNA targeting Plk4 (AGATAGCAATTATGTGTATC) was cloned into the PX459 expression 
vector that co-expresses the gRNA from a U6 promoter and SpCas9 from a CMV promoter. 
Cells were co-transfected with a 1:20 ratio of the PX459 plasmid and a 160 bp single-stranded 
oligonucleotide repair template. The repair template introduced the L89G mutation, a silent 
AflIII restriction site and a mutation in the SpCas9 protospacer adjacent motif (PAM) to prevent 
re-cutting after homology directed repair. Transfected cells were selected for two days with 
puromycin and single clones isolated by limiting dilution. Genomic DNA was isolated from 
single clones and subjected to PCR using the following primers (For: 
GCAGGAATGGTACAGAGAGTCC, Rev: GCAAAACTTTTATCCACCCAAA). PCR 
products were digested with AflIII for 2 hours. Clones with digested PCR products were 
sequenced to verify insertion of the L89G mutation. Two independent homozygous L89G clones 
were identified and behaved identically in all assays performed.  
 





Drosophila S2 cell culture and transfection 
Drosophila S2 cells (a kind gift from Ji Hoon Kim) were cultured at room temperature in vented 




cells were seeded in a 6-well plate in 2 mL media.  The following day cells were transfected with 
the indicated constructs using Effectene (QIAGEN) according to the manufacturer’s protocol.  
Cells were harvested 48 hours later and subjected to co-immunoprecipitation (procedure below). 
 
Cloning 
All DNA constructs were cloned into a pcDNA
TM
5/FRT/TO vector backbone (Life 
Technologies) and expressed from a CMV promoter under the control of two Tetracycline 
operator sites.  All constructs were full-length proteins unless otherwise noted. DNA constructs 
for Drosophila S2 transfection were cloned into a pAc
TM
 vector backbone (Invitrogen). 
 
Generation of stable cell lines and siRNA treatment  
Stable, isogenic cell lines expressing Myc-GFP-STIL from a CMV promoter under the control of 
two Tetracycline operator sites were generated according to the manufacturer’s recommendation 









Core Kit). Expression of Myc-GFP-STIL was induced with 1 µg/ml 
Tetracycline (Sigma), and expression of Myc-GFP-CPAP was induced with 2 ng/mL 
Tetracycline. Expression of Myc-STIL-T2A-GFP-CPAP constructs were induced with 1 µg/mL 
Tetracycline. For RNA interference, 2 x 10
5
 cells were seeded in a 6-well plate and duplexed 
siRNAs introduced using RNAiMax (Life Technologies). siRNA directed against STIL (5’-
GCUCCAAACAGUUUCUGCUGGAAU-3’) and CPAP (5’-
AGAAUUAGCUCGAAUAGAAUU-3’) were purchased from Dharmacon and control siRNA 
(Universal Negative Control #1) was purchased from Sigma. Tetracycline was added to induce 
expression of RNAi-resistant Myc-GFP-STIL or Myc-STIL-T2A-GFP-CPAP. Expression of 
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Myc-GFP-CPAP transgene was induced concurrently with siRNA treatment. Cells were 
harvested and processed for immunoblotting or fixed for immunofluorescence 24 hours later. 
 





-DLD-1 cell lines were generated by culturing lines in centrinone at 
500 nM for seven or more days.  Cells were subjected to the siRNA protocol (above).  24 hours 
later, centrinone was washed out where noted by replacing media twice on cells for ten minutes 
each and then resuspending cells across multiple coverslips and adding Tetracycline at given 
concentrations depending on the cell line (concentrations above).  Cells were fixed at 24, 48, and 
72 hours post-washout as described below. 
 
Cell biology 
To prepare cells for flow cytometry, cell pellets were fixed in cold 70% EtOH for 24 hours, 
washed once in PBS and suspended in PBS supplemented with 0.5 mg/ml RNAse A and 50 
mg/ml Propidium Iodide (PI). Samples were incubated at room temperature for 30 minutes and 
analyzed on a flow cytometer (FACSCalibur; Becton Dickinson). For metaphase spreads, cells 
were treated for up to 4 hours with 3.3 μM nocodazole, then incubated in 0.45% hypotonic buffer 
(32 mM KCl, 16 mM Hepes, 0.5 mM EDTA pH 7.4) at 37°C for 20 minutes. Cells were fixed in 
methanol:acetic acid (3:1) and stored at –20°C overnight. Fixed cells were dropped onto acetic-
acid-coated slides and air-dried. Chromosomes were stained with Hoechst, mounted and imaged. 
For clonogenic assays 500 cells were seeded in a 10cm
2
 culture dish and left to grow for ~ 2 
weeks until colonies were visible by eye. Cells were fixed in methanol for 10 minutes at room 






 293-FT cells were seeded into 10 cm
2
 dishes and 24 hours later transfected with 2 µg of 
plasmid DNA. 48 hours later, transfected cells were lysed in lysis buffer [10 mM Tris pH 7.5, 
0.1% Triton X-100, 300 mM NaCl, 1 mM EDTA, 50 mM NaF, 50 mM β-glycerophosphate, 1 
mM DTT, 500 nM microcystin, 1 mM PMSF and EDTA-free protease inhibitor tablet (Roche)], 
sonicated and soluble extracts prepared. The supernatant was incubated with beads coupled to 
GFP-binding protein (Rothbauer et al. 2007). Alternatively, 2 µg of anti-mCherry antibody 
(rabbit, a kind gift from Joo Soek-Han) was added per sample and collected using Affi-Prep 
Protein A (Bio-Rad) (Figure 5G). Beads were washed 3 times in lysis buffer and immunopurified 
protein analyzed by immunoblot. For lambda phosphatase treatment, cells were lysed in lambda 
phosphatase buffer (New England BioLabs) and soluble lysates incubated with 2µL of Lambda 
Protein Phosphatase (New England BioLabs) for 60 minutes at 30°C. 
 
Immunoblotting and immunofluorescence 
For immunoblot analysis, protein samples were separated by SDS-PAGE, transferred onto 
nitrocellulose membranes with a Trans-Blot Turbo Transfer System (BioRad) and then probed 
with the following antibodies: DM1A (mouse anti-α-tubulin, Sigma, T6199, 1:5000), STIL 
(rabbit, Bethyl, A302-441A, 1:2500), FLAG M2 (mouse, Sigma, F1804, 1:1000), CPAP (rabbit, 
a kind gift from Karen Oegema, 1:1000), HA (rat, 3F10, Roche, 1:1000), Myc 4A6 (mouse, 
EMD Millipore 1:1000), SAS6 (mouse, Santa Cruz, sc-81431, 1:1000), Plk4 pT170 (rabbit, a 
kind gift from Mutsuhiro Takekawa, 1:1000) in Figure 5G (Nakamura, Saito, and Takekawa 
2013),  Plk4 pT170 (rabbit, this study, 1:1000) for all other figures, Plk4 (rabbit, this study, 
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1:3200), mCherry (rabbit, a kind gift from Joo Soek-Han, 1:1000), STIL pS1116 (rabbit, this 
study, 1:250), and STIL pS428 (rabbit, this study, 1:1000). Blots were blocked with 3% BSA in 
PBST and washed with PBST.  Phospho-antibody blots were blocked in TBS Starting Block 
(Thermo) supplemented with 0.05% Tween 20 and washed in TBST.  Antibodies were diluted in 
respective blocking buffers. 
 
For immunofluorescence, cells were grown on 18-mm glass coverslips and fixed in 100% ice 
cold methanol for 10 min. Cells were blocked in 2.5% FBS, 200 mM glycine, 0.1% Triton X-100 
in PBS for 1 h. Antibody incubations were conducted in the blocking solution for 1 h. DNA was 
detected using DAPI, and cells were mounted in Prolong Antifade (Invitrogen). Staining was 
performed with the following primary antibodies: GTU-88 (mouse anti-γ-tubulin, Abcam, 
1:250), Centrin (mouse, Millipore, 04-1624, 1:1000), Centrin (rabbit, directly-conjugated, this 
study, 1:1000), CNAP (guinea pig, raised against the CNAP peptide sequence 
SPTQQDGRGQKNSDAKC, a kind gift from Olaf Stemmann, University of Bayreuth, 
Germany, 1:1000), CEP152 (rabbit, Bethyl, A302-479A, 1:5000), Plk4-650 (directly-labeled 
rabbit, this study, 1:1000), STIL-550 (directly-labeled rabbit, this study, 1:1000), STIL pS1108 
(rabbit, this study, 1:250), CEP135 (rabbit, raised against CEP135 a.a. 695-838, a kind gift from 
Anthony Hyman, Max Planck Institute for Molecular Cell Biology and Genetics, Germany, 
1:1000), CEP192-Cy3 (directly-labeled rabbit, raised against CEP192 a.a. 1-211, a kind gift from 
Karen Oegema, Ludwig Institute for Cancer Research, CA, 1:1000), SAS6 (mouse, sc-81-431 
Santa Cruz, 1:1000), SAS6-Cy3 (directly-labeled rabbit, raised against SAS6 a.a. 501-657, a 
kind gift from Karen Oegema, Ludwig Institute for Cancer Research, CA,1:1000), CPAP-Cy3 
(directly-labeled rabbit, a kind gift from Karen Oegema, Ludwig Institute for Cancer Research, 
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CA,1:1000) and, CEP192 (goat, directly-labeled, this study, 1:000), CENP-F (sheep, raised 
against CENP-F a.a. 1363-1640, a kind gift from Stephen Taylor, the University of Manchester, 
UK,1:1000). Secondary donkey antibodies were conjugated to Alexa Fluor® 488, 555 or 650 
(Life Technologies). 
 
For the cell cycle analysis of STIL levels shown in Figure 10C, cells were pulsed with EdU for 1 
hour prior to fixation in 100% ice cold methanol at -20°C for 10 minutes. Cells were washed 3 x 
with 0.1% Triton X-100 in PBS and stained using a Click-It EdU Alexa Fluor 555 imaging kit 
(Life Technologies) according to the manufacturer’s recommendations. Cells were blocked in 
2.5% FBS, 200 mM glycine, 0.1% Triton X-100 in PBS for 1 hour and immunofluorescence 
microscopy performed using the following antibodies: CENP-F, GTU-88 and STIL-550. G1 
phase cells were classified as CENP-F and EdU negative, S phase cells were classified as EdU 
positive and G2 phase cells were classified as CENP-F positive and EdU negative. The γ-tubulin 
staining was used to define the position of the centrosome.  
 
Immunofluorescence images were collected using a Deltavision Elite system (GE Healthare) 
controlling a Scientific CMOS camera (pco.edge 5.5). Acquition parameters were controlled by 
SoftWoRx suite (GE Healthare). Images were collected at room temperature using an Olympus 
60 x 1.42 NA or Olympus 100x 1.4 NA oil objective at 0.2 μM z-sections and subsequently 
deconvolved in SoftWoRx suite. Images were acquired using Applied Precision immersion oil 
(N=1.516).  For quantitation of signal intensity at the centrosome, deconvolved 2D maximum 
intensity projections were saved as 16-bit TIFF images. Signal intensity was determined using 
ImageJ, by drawing a circular region of interest (ROI) around the centriole (ROI S). A larger 
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concentric circle (ROI L) was drawn around ROI S. ROI S and L were transferred to the channel 
of interest and the signal in ROI S was calculated using the following formula: IS – [(IL-IS/AL-
AS) x AS] 
A =Area, I=Integrated pixel intensity. 
 
Fluorescence recovery after photobleaching 
Cells were seeded into 4-chamber, 35mm glass bottom culture dishes (Greiner) and maintained 
in cell culture medium at 37C and 5% CO2 in an environmental control station. Images were 
collected using a Zeiss 40x 1.4 NA PlanApochromat oil-immersion objective on a Zeiss LSM 
780 confocal equipped with a solid-state 488 nm laser and a spectral GaAsP detector. Images 
were acquired using Carl Zeiss immersion oil (N=1.518).  Acquisition parameters, shutters, and 
focus were controlled by Zen black software (Zeiss). 10 X 0.5 µM z-sections were acquired for 
EGFP at each time point. Two consecutive pre-bleach scans were collected at 5% of the 
maximum ATOF value. Centrosome localized Myc-EGFP-STIL or EGFP-CPAP was bleached 
within a circular region encompassing the centrosome (~ 3 µM in diameter) at 100% laser power 
with 100 µsec dwell time. Post-bleach scans were performed at 20-second time intervals for a 
total period of 400 seconds. Maximum intensity projections were created using Zen black. The 
integrated intensity value within a circular region of interest in the cytosol of the cell was 
subtracted from an identically sized region of interest drawn around the bleached centrosome. 
Recovery values were plotted relative to the difference between the fluorescence pre- and post-
bleach.  
 
Recombinant protein expression and purification  
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GFP-binding protein (GBP), recombinant His-hPlk4 (a.a. 1-416), and GST-Flag-CPAP TCP 
domain (aa 1142-1338) were expressed and purified from E.coli [strain Rosetta (DE3)] using 
standard procedures. Recombinant GST-hPlk4, GST-hSAS6, GST-hSTIL and GST-hSTIL C-
term (a.a. 898-1287) were expressed and purified from High Five insect cells (Invitrogen) using 
the Bac-to-Bac expression system (Invitrogen). Infected cell pellets were suspended in lysis 
buffer (10 mM PO4
3- 
pH 7.4, 137 mM NaCl, 2.7 mM KCl, 10% glycerol, 2 mM MgCl2, 5 mM 
DTT, 100 nM Microcystin, 1 mM Na3V04, 250 U of Benzonaze nuclease (Sigma), 1 mM PMSF 
and EDTA-free protease inhibitor tablet (Roche)) and lysed by sonication. After centrifugation at 
15,000 rpm
 
for 30 min, the supernatant was supplemented with 110 mM KCL and 0.1% Triton 
X-100 and incubated
 
with Glutathione Sepharose beads (GE Healthcare) for 4 h at 4°C. Beads 
were washed extensively in wash buffer [10 mM PO4
3- 
pH 7.4, 137 mM NaCl, 2.7 mM KCl, 
10% glycerol, 5 mM DTT, 0.1% Trition X-100, 100 mM KCL, 1 mM PMSF and EDTA-free 
protease inhibitor tablet (Roche)] and protein eluted in elution buffer (10 mM PO4
3- 
pH 7.4, 137 
mM NaCl, 2.7 mM KCl, 10% glycerol, with 40 mM reduced glutathione and 5 mM DTT). 
Protein was dialyzed into a final buffer of 10 mM PO4
3- 
pH 7.4, 137 mM NaCl, 2.7 mM KCl, 
10% glycerol. When necessary, the GST tag was removed by overnight incubation with GST-
PreScission protease (GE Healthcare). 
 
In vitro kinase assay 
Assays were conducted for 30 minutes at 30°C in 20 mM Tris pH 7.5, 25 mM KCl, 1 mM DTT, 
and in the presence of 10 mM MgCl2 and 100 µM ATP.  2 µg of substrate was incubated with 1 
µg of of His-hPlk4 (a.a. 1-416). Kinase reactions were stopped with sample buffer and analyzed 
by SDS-PAGE and western blotting. 
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In vitro binding assay 
For STIL-SAS6 binding, recombinant GST-hSTIL or GST-hSTIL C-term (a.a. 898-1287) was 
incubated with kinase active or kinase dead His-hPlk4 (a.a. 1-416) in kinase buffer with or 
without cold ATP as above. Reactions were then supplemented with 500 µl of binding buffer (50 
mM Na-HEPES pH 7.5, 100 mM NaCl, 2 mM MgCl2, 1 mM EGTA, 1 mM DTT, 0.1 % Triton-
X 100, 100 nM Microcystin (Calbiochem) and 0.5 mg/ml BSA) and incubated at 4°C for 1 hour. 
Glutathione Sepharose beads (GE Healthcare) was incubated with the protein for a further 1 hour 
at 4°C. Beads were washed three times in binding buffer without BSA and proteins eluted in 
SDS sample buffer. 
 
For STIL-CPAP binding, Recombinant GST-hSTIL was bound to GSH resin (GoldBio) for four 
hours at 4°C in PBS, 10% glycerol, and 1 mM DTT.  Beads were washed twice in kinase buffer 
(see above) supplemented with 10% glycerol and incubated with 6xHis-hPlk4 (a.a. 1-416) in 
kinase buffer with or without 10 µM cold ATP at 33°C for two hours. Reactions were then spun 
down and washed twice with cold binding buffer (50 mM Na-HEPES pH 7.5, 400 mM NaCl, 2 
mM MgCl2, 1 mM EGTA, 1 mM DTT, 0.15 % Triton-X 100, 100 nM Microcystin (Calbiochem) 
and 0.5 mg/ml BSA) and spun in binding buffer at 4°C for 2 hours in the presence of 
recombinant Flag-CPAP TCP domain. Beads were washed three times in binding buffer without 




In-solution protein digestion was carried out using "Filter Assisted Sample Preparation" (FASP) 
method . Data dependent MS/MS analysis of peptides was carried out on the LTQ-Orbitrap 
Velos (www.thermoscientific.com) interfaced with Eksigent 2D nanoflow liquid 
chromatography system (www.eksigent.com system). Peptides were enriched on a 2 cm trap 
column (YMC gel ODS-A S-10µm), fractionated on a 75 µm x 15 cm column packed with 5µm, 
100Å Magic AQ C18 material (Michrom Bioresources), and electrosprayed through a 15 µm 
emitter (PF3360-75-15-N-5, New Objective). Reversed-phase solvent gradient consisted of 0.1% 
formic acid with increasing levels of 0.1% formic acid, 90% acetonitrile over a period of 90 
minutes. LTQ orbitrap Velos was set at 2.0 kV spray voltage, full MS survey scan range was set 
at 350-1800 m/z, data dependent HCD MS/MS analysis set for top 8 precursors with minimum 
signal of 2,000. Other parameters include peptide isolation width of m/z 1.9; dynamic exclusion 
limit 30s and normalized collision energy 35; precursor and the fragment ions resolutions were 
30,000 and 15,000, respectively. Internal mass calibration was applied using lock mass ion m/z = 
371.101230. 
 
Mass spectrometry raw files were automatically processed through Proteome Discoverer 1.4 
software. Raw MS and MS/MS data was isotopically resolved with deconvolution and 
deisotoping using Thermo Scientific Xtract and MS2-processor software in addition to default 
spectrum selector node. The data was searched in Refseq human entries using Mascot (v2.2.6, 
Matrix Sciences) search engine interfaced with different processing nodes of Proteome 
Discoverer 1.4. Mass tolerances on precursor and fragment masses were set to 15 ppm and 0.03 
Da, respectively. Peptide validator node was used for identification confidence and 1% false 
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discovery rate cutoff was used to filter the peptides. Phosphorylation site probability was 
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